ESH-OnAir Programma Web96media

ON-A I R
April 11-14, 2021
SCIENTIFIC PROGRAMME
SUNDAY, APRIL 11 SCIENTIFIC PROGRAMME
11.00-12.00 - AUDITORIUM 12.00-12.45 - AUDITORIUM
OPENING OF THE CONGRESS Minisymposium

Chairperson: A.F. Dominiczak (Glasgow, UNITED KINGDOM) supported by Omron Healthcare
ADVANCES IN TECHNOLOGY, PIONEERING NEW

Welcome: PRACTICES IN NOCTURNAL HYPERTENSION
A.F. Dominiczak (Glasgow, UNITED KINGDOM) ASSESSMENT IN PATIENTS AT RISK
G. Mancia (Milan, ITALY)
U. Martin (Birmingham, UNITED KINGDOM) Chairperson: G. Parati (Milan, ITALY)
R. Kreutz (Berlin, GERMANY)
A. Schutte (Sidney, AUSTRALIA)
12.00-12.05 Introduction
LECTURE G. Parati (Milan, ITALY)
Future of hypertension: time for transformation
V.J. Dzau (Washington, DC, USA) 12.05-12.15 New approach to nocturnal hypertension assessment
B. Sanner (Wuppertal, GERMANY)
12.15-12.25 Patient populations at risk for cardiac events related to

nocturnal hypertension
F.P. Cappuccio (Coventry, UNITED KINGDOM)
12.25-12.35 Casuistry: consequences of nocturnal hypertension in

practice
D. Schoors (Brussels, BELGIUM)
12.35-12.45 Q&A
3
12.00-13.00 - ROOM 1 12.00-12.45 - ROOM 2
Joint Session ESH-ISH-POA Minisymposium

supported by an unrestricted educational grant from Sanofi
EFFECTIVE PRECISION DIAGNOSIS AND THERAPIES
OF HYPERTENSION FOR CLINICIANS QUESTIONS AT THE START OF HYPERTENSION
Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM), TREATMENT IN CLINICAL PRACTICE:
J.B. Park (Seoul, SOUTH KOREA) A CASE-BASED INTERACTIVE SESSION
Chairpersons: R. Kreutz (Berlin, GERMANY),
A. Schutte (Sydney, AUSTRALIA)
12.00-12.13 Molecular networking in hypertension
R.M. Touyz (Glasgow, UNITED KINGDOM)
12.00-12.05 The 2018 ESC/ESH core-treatment strategy:
12.13-12.18 Comments importance of SPCs*
C. Delles (Glasgow, UNITED KINGDOM) R. Kreutz (Berlin, GERMANY)
12.18-12.31 Precise vascular phenotype of blood pressure per se The 2018 ESC/ESH and 2020 ISH core-treatment
P. Boutouyrie (Paris, FRANCE) strategy: importance of SPCs*
12.31-12.36 Comments
J.-W. Ha (Seoul, SOUTH KOREA) 12.05-12.15 CASE 1: Always and which type of RAS-blocker as
backbone of therapy?
12.36-12.49 Digital transformation and artificial intelligence for P. van de Borne (Brussels, BELGIUM)
precise hypertension
K. Kario (Tochigi, JAPAN) 12.15-12.25 CASE 2: Which patient should be still started with
monotherapy?
12.49-12.54 Comments J. Brguljan (Ljubljana, SLOVENIA)
T. Weber (Wels, AUSTRIA)
12.25-12.35 CASE 3: Which patient should be referred to a
12.54-13.00 Discussion specialist?
A. Januszewicz (Warsaw, POLAND)
12.35-12.45 General Discussion
*Single Pill Combinations
4
12.00-13.00 - ROOM 3
12.35-12.45 Strategies to prevent salt-induced hypertension
19 International SHR Symposium
th T. Kurtz (San Francisco, CA, USA)
12.45-12.55 Metabolic syndrome in spontaneously hypertensive rats

GENETICS AND DISEASE MODEL GUIDED NOVEL M. Pravenec (Prague, CZECH REPUBLIC)
THERAPEUTIC TARGET DISCOVERY
IN HYPERTENSION 12.55-13.00 Discussion
Chairpersons: Y. Yamori (Nishinomiya-City, JAPAN),
T. Nabika (Izumo, JAPAN),
T. Guzik (Glasgow, UNITED KINGDOM)
12.00-12.05 Opening Remarks and Welcome Speech

Y. Yamori (Nishinomiya-City, JAPAN), T. Nabika (Izumo,
JAPAN), T. Guzik (Glasgow, UNITED KINGDOM)
12.05-12.15 Integrative genomic analysis of blood pressure in rats

N. Kato (Tokyo, JAPAN)
12.15-12.25 What genetics of blood pressure teaches us about

future therapies
M.J. Caulfield (London, UNITED KINGDOM)
12.25-12.30 Brain perivascular macrophages contribute to the

development of hypertension through sympathetic
activation in stroke-prone spontaneously hypertensive
rats
K. Shinohara, T. Iyonaga, Y. Hirooka, H. Tsutsui
(Fukuoka, JAPAN)
12.30-12.35 Effects of blood pressure and salt on arterial lipid

deposition in the apoe-depleted shr
H. Matsuo, K. Kawakami, K. Fujikawa, H. Ohara,
T. Yamada, T. Nabika (Izumo, JAPAN)
5
12.00-14.00 - ROOM 4
BIHS Symposium
SESSION 1: SESSION 2:
OLD AND NEW CHALLENGES IN PRIMARY CARE REMOTE CONSULTATIONS AND VIRTUAL CLINICS
Chairpersons: U. Martin (Birmingham, UNITED KINGDOM),
J. Moore (London, UNITED KINGDOM)
U. Martin (Birmingham, UNITED KINGDOM),
U. Martin (Birmingham, UNITED KINGDOM),
13.05-13.25 Remote consultations and virtual clinics: experience
from COVID-19

M. Glover (Nottingham, UNITED KINGDOM)
12.05-12.25 Measuring BP in primary care: practical aspects and
the role of AHPs
13.25-13.35 Home blood pressure measurement: opportunities and
S. McDonagh (Exeter, UNITED KINGDOM)
challenges
T. McCormack (London, UNITED KINGDOM)
12.25-12.35 Adherence and treatment resistance
I. Mackenzie (Dundee, UNITED KINGDOM)
13.35-13.45 Advances in telemonitoring
R. McManus (Oxford, UNITED KINGDOM)
12.35-12.45 Hypertensive emergencies: same day referral to
secondary care
13.45-14.00 Panel discussion and Q&A
M. Okorie (Brighton, UNITED KINGDOM)
12.45-13.00 Panel discussion and Q&A
6
12.00-13.00 - ROOM 5 12.30-13.30 - ROOM 6
ESH Working Group on Hypertension and ESH Working Group on Interventional

the Brain Treatment of Hypertension
Chairpersons: R.E. Schmieder (Erlangen, GERMANY),
SUPPORTING ROUTINE ASSESSMENT OF COGNITIVE K. Tsioufis (Athens, GREECE)
FUNCTION IN HYPERTENSIVE PATIENTS: A POSITION
PAPER OF THE WG 12.30-12.40 Comparison of the evidence of various approaches
Chairpersons: P. Cunha (Guimarães, PORTUGAL), K. Dimitriadis (Athens, GREECE)
E. Manios (Athens, GREECE)
12.40-12.50 Vascular Stiffness: How to assess and its predictive role
for BP response
12.00-12.12 What is the burden of the dementia in hypertensive C. Ott (Erlangen, GERMANY)
patients and associated disability?
C. Tzourio (Bordeaux, FRANCE) 12.50-13.00 Update on techniques beyond renal denervation
F. Mahfoud (Homburg/Saar, GERMANY)
12.12-12.24 What is the relationship between blood pressure,
cognitive function and dementia? 13.00-13.10 Update on renal denervation in renal and cardiac
C. Qiu (Stockholm, SWEDEN) disease
M. Schlaich (Perth, AUSTRALIA)
12.24-12.36 Antihypertensive treatment and dementia
A. Vicario (Buenos Aires, ARGENTINA) 13.10-13.30 Podium discussion
D. Hering (Gdansk, POLAND), K. Kario (Tochigi, JAPAN)
12.36-12.48 Additional factors for cognitive impairment of greater
relevance when managing older hypertensive patients/
special populations?
A. Scuteri (Sassari, ITALY)
12.48-13.00 Recommendations of the WG on Hypertension and the

Brain
P. Cunha (Guimarães, PORTUGAL)
7
13.00-14.00 - AUDITORIUM 13.00-14.00 - ROOM 1
Satellite Symposium ESH Working Group on Vascular Structure

supported by Servier and Function
THE EVOLUTION OF HYPERTENSION MANAGEMENT: DEFINING A NOVEL APPROACH FOR VALIDATION OF
THE INCREASING ROLE OF TRIPLE THERAPY IN NEW DEVICES FOR ARTERIAL
CLINICAL PRACTICE STIFFNESS MEASUREMENT
Chairpersons: G. Mancia (Milan, ITALY), Chairpersons: B. Spronck (New Haven-CT, USA),
K. Narkiewicz (Gdansk, POLAND) D. Terentes-Printzios (Athens, GREECE)
13.00-13.05 Introduction 13.00-13.05 Introduction

G. Mancia (Milan, ITALY) B. Spronck (New Haven-CT, USA)
13.05-13.25 Triple single-pill combination: what do the guidelines 13.05-13.20 How to improve previous guidelines?
tell us? A. Avolio (Sydney, AUSTRALIA)
K. Narkiewicz (Gdansk, POLAND)
13.20-13.35 The experience with BP measuring devices
13.25-13.45 Pros and cons of RAAS inhibitors and diuretics J. Sharman (Hobart, AUSTRALIA)
A.A. Brandão (Rio de Janeiro, BRAZIL)
13.35-13.50 Where do we stand?
13.45-14.00 Discussion and conclusion R.M. Bruno (Paris, FRANCE)
13.50-14.00 Discussion
8
13.00-14.00 - ROOM 2 13.00-14.00 - ROOM 3
ESH Working Group on Obesity, Diabetes ESH Working Group on Hypertension

and the High Risk Patient and Cardiovascular Risk Assessment in
Subjects Living in or Emigrating from Low
WOMEN A HIGH RISK POPULATION:
REPRODUCTION, HORMONES AND Resource Settings
CARDIOVASCULAR RISK
COMPREHENSIVE APPROACH FOR HYPERTENSION
Chairpersons: V. Kotsis (Thessaloniki, GREECE), CONTROL IN AFRICA
G. Grassi (Milan, ITALY)
Chairperson: P.A. Modesti (Florence, ITALY)
13.00-13.10 Early life programming of CVD

P.M. Nilsson (Malmö, SWEDEN) 13.00-13.10 The new epidemiology of hypertension in Africa
A. Damasceno (Maputo, MOZAMBIQUE)
13.10-13.20 RAS system treatment and offspring outcome in
pregnancy 13.10-13.20 Healthcare provider education for home and community
S. Stabouli (Thessaloniki, GREECE) based interventions
13.20-13.30 Hypertension in pregnancy
V. Kotsis (Thessaloniki, GREECE) 13.20-13.30 Metodological issue for cardiovascular risk stratification
in low resource settings
13.30-13.40 Maternal pregnancy obesity and offspring adult CV risk P.A. Modesti (Florence, ITALY)
V. Katsi (Athens, GREECE)
13.30-13.40 Effective, practical, and sustainable intervention
13.40-13.50 Contraceptives, hormones and hypertension programs for hypertension management in Africa
C. Antza (Thessaloniki, GREECE) F. Jarraya (Sfax, TUNISIA)
13.50-14.00 Discussion 13.40-13.50 The need for a global call to action

G. Parati (Milan, ITALY)
9
13.00-14.00 - ROOM 5 13.30-14.30 - ROOM 6
ESH Working Group on Cardiovascular ESH Working Group on Hypertension and

Pharmacotherapy and Adherence the Heart
Chairpersons: M. Burnier (Lausanne, SWITZERLAND),
A. Persu (Brussels, BELGIUM) HYPERTENSION IS THE MOST IMPORTANT CAUSE
OF HFpEF: MECHANISMS AND MANAGEMENT
Chairpersons: E. Agabiti Rosei (Brescia, ITALY),
Constitution of the new working group and list of participants K. Tsioufis (Athens, GREECE)

Election of the board: chairman, secretary and 2-3 members
13.30-13.42 Epidemiological aspects
Presentation of the statutes of the Working Group M. Camafort (Barcelona, SPAIN)

Discussion of projects: papers-research projects-initiatives 13.42-13.54 Pathophysiological mechanisms for the development of
HFpEF in hypertension
Short presentation of the results of the ESH Adherence survey A. Kasiakogias (Athens, GREECE)
13.54-14.06 The management of hypertensive patients with HFpEF.

Which role for ARNI and/or SGLT 2 inhibitors
C. Grassos (Athens, GREECE)
14.06-14.30 Organization and future projects of the WG

Hypertension and the heart
10
14.00-15.00 - AUDITORIUM 14.00-15.00 - ROOM 1
Satellite Symposium ESH Working Group on Hypertension in

supported by Medtronic Children and Adolescents
RENAL DENERVATION: A NOVEL APPROACH TO HYPERTENSION IN YOUTH: NEW INSIGHTS
HYPERTENSION CARE
Chairpersons: G. Mancia (Milan, ITALY),
Chairperson: K. Tsioufis (Athens, GREECE) E. Wühl (Heidelberg, GERMANY)
14.00-14.05 Session discussion and live introduction 14.00-14.25 Hypertension and cerebrovascular disease
K. Tsioufis (Athens, GREECE) S. Stabouli (Thessaloniki, GREECE)
14.05-14.15 The evidence for radiofrequency ablation as a 14.25-14.50 HyperChildNET: Towards the future of hypertension in
hypertension treatment option children and adolescents
A. Sharp (Cardiff, UNITED KINGDOM) E. Lurbe (Valencia, SPAIN)
14.15-14.25 Emerging consensus for renal denervation: regional 14.50-15.00 Discussion

perspectives
J.A. García Donaire (Madrid, SPAIN)
14.25-14.50 Renal denervation in the real-world: performance in

high risk subgroups
R.E. Schmieder (Erlangen, GERMANY),
14.50-15.00 Live Q&A

K. Tsioufis (Athens, GREECE)
11
14.00-15.00 - ROOM 2 14.00-15.00 - ROOM 3
ESH Working Group on Hypertension and ESH Working Group on Endothelins and
the Kidney Endothelial Factors
ADVANCES ON DIAGNOSIS, PATHOPHYSIOLOGY UNSOLVED ISSUES IN ENDOTHELIAL DYSFUNCTION
AND TREATMENT OF HYPERTENSION IN IN ARTERIAL HYPERTENSION
PATIENTS WITH CKD Chairpersons: G.P. Rossi (Padua, ITALY) ,
Chairpersons: J.-M. Halimi (Tours, FRANCE), T.M. Seccia (Padua, ITALY)
P. Sarafidis (Thessaloniki, GREECE)
M. Barton (Zurich, SWITZERLAND)

14.00-14.10 Diagnostic and prognostic utility of out-of-office BP D. Rizzoni (Brescia, ITALY)
monitoring in CKD N. Dhaun (Edinburgh, UNITED KINGDOM)
G. Parati (Milan, ITALY) T.M. Seccia (Padua, ITALY)
14.10-14.20 The effects of sleep quality on overall BP control in

CKD
G. Bakris (Chicago, IL, USA)
14.20-14.30 Mineralo corticoid receptor antagonists for

nephroprotection: an old concept revisited?
L.M. Ruilope (Madrid, SPAIN)
14.30-14.40 SGLT-2 inhibitors for nephroprotection in non-diabetic

patients with CKD
P. Sarafidis (Thessaloniki, GREECE)
14.40-14.50 Hypertension in patients with renal transplantation:

current concepts and future directions
J.-M. Halimi (Tours, FRANCE)
12
14.00-15.00 - ROOM 4
ESH Working Group on Hypertension and CASE 3

14.36-14.46 Patient on multiple antihypertensive therapy
Sexual Dysfunction K. Stavropoulos (Thessaloniki, GREECE)
SEXUAL DYSFUNCTION AND ANTIHYPERTENSIVE 14.46-14.48 Discussion

THERAPY A. Pittaras (Athens, GREECE)
Chairpersons: D. Lovic (Niš, SERBIA), CASE 4

M. Viigimaa (Tallinn, ESTONIA) 14.48-14.58 Addition of PDE-5 inhibitors
M. Doumas (Thessaloniki, GREECE)
14.00-14.12 Current clinical practice and future directions 14.58-15.00 Discussion

C. Vlachopoulos (Athens, GREECE) J. Brguljan (Ljubljana, SLOVENIA)
CASE 1
14.12-14.22 Patient on diuretics
D. Terentes-Printzios (Athens, GREECE)
M. Doumas (Thessaloniki, GREECE)
CASE 2
14.24-14.34 Patient on beta-blockers
K. Imprialos (Thessaloniki, GREECE)
V. Stojanov (Belgrade, SERBIA)
13
14.00-15.00 - ROOM 5 15.00-15.45 - AUDITORIUM
ISH Regional Advisory Group - Africa Minisymposium

Chairpersons: H. Beheiry (Khartoum, SUDAN), supported by Servier
B. Williams (London, UNITED KINGDOM)
ELEVATED HEART RATE IN HYPERTENSIVE PATIENTS
Chairpersons: G. Grassi (Milan, ITALY),
14.00-14.05 ISH Africa Regional Advisory Group (RAG) introduction G. Mancia (Milan, ITALY)
and objectives
A. Odili (Abuja, NIGERIA)
15.00-15.15 Is it important to take heart rate into consideration
14.05-14.20 Hypertension in Africa: changing pattern of disease and while treating hypertensive patients?
challenge of data G. Mancia (Milan, ITALY)
A. Odili (Abuja, NIGERIA)
15.15-15.30 How can we individualize treatment of hypertensive
14.20-14.35 May Measurement Month in Africa: a three-year review patients with elevated heart rate?
and future plan S. Masi (Pisa, ITALY)
15.30-15.45 Discussion and conclusion
14.35-14.50 Roadmap to achieve 25% hypertension control in Africa
by 2025: challenges and way forward
A. Dzudie (Yaounde, CAMEROON)
14
15.00-15.45 - ROOM 1 15.00-15.45 - ROOM 2
Minisymposium Minisymposium
supported by Bayer supported by Menarini Group
PROTECTING THE BRAIN: WHY KIDNEYS MATTER? LESSON FROM THE COURTROOM
Chairperson: R. Kreutz (Berlin, GERMANY) Chairpersons: G. Ambrosio (Perugia, ITALY),
C. Borghi (Bologna, ITALY)
15.00-15.03 Welcome and introduction

R. Kreutz (Berlin, GERMANY) 15.00-15.05 Hypertension burden and spotlight on ESC-ESH
Guidelines
15.03-15.15 AF and hypertension: Implications for the brain and G. Ambrosio (Perugia, ITALY)
beyond
R. Kreutz (Berlin, GERMANY) 15.05-15.15 ACE-Is as a pillar of hypertension management
G. Ambrosio (Perugia, ITALY)
INTERVIEW STYLE
15.15-15.30 Why should we consider the kidneys throughout our 15.15-15.30 Only people are the same in front of the law, molecules
patient’s AF journey? are different!
R. Kreutz (Berlin, GERMANY), G. Baron-Esquivias (Sevilla, C. Borghi (Bologna, ITALY)
SPAIN)
15.30-15.35 Further evidences under the magnifying glass
INTERVIEW STYLE C. Borghi (Bologna, ITALY)
15.30-15.45 How can we protect our patients with AF from stroke
and kidney function decline? 15.35-15.45 Final remarks and Q&A
R. Kreutz (Berlin, GERMANY), M. Arici (Ankara, TURKEY) G. Ambrosio (Perugia, ITALY), C. Borghi (Bologna, ITALY)
15
15.00-16.00 - ROOM 3 15.00-16.00 - ROOM 4
The Balkan Symposium Oral Session 1A

Chairpersons: S. Karanovic (Zagreb, CROATIA),
S. Stabouli (Thessaloniki, GREECE), CARDIOVASCULAR RISK FACTORS
V. Stojanov (Belgrade, SERBIA) Chairpersons: E. Lurbe (Valencia, SPAIN)
U.M. Steckelings (Odense, DENMARK)
15.00-15.10 BP CON ESH-report on first 3000 subjects

A. Triantafyllou (Thessaloniki, GREECE), 15.00 NEUTROPHIL TO LYMPHOCYTE RATIO AND PLATELET
S. Karanovic (Zagreb, CROATIA) TO LYMPHOCYTE RATIO AS ASSESSMENT TOOLS FOR LIPID
CONTROL AND CARDIOVASCULAR RISK
15.10-15.20 Cardiac damage in adult hypertensive population from A. M. Vintila, M. Horumba, C. Cimpu, D. Dumitrescu, P. Miron, A. Alucai,
a high cardiovascular risk Country-SEPHAR III survey G. Gabriel Cristea, V. D. Vintila
A. Vijiiac (Bucharest, ROMANIA) Bucharest, ROMANIA
15.20-15.30 Results of the Hevro study 15.07 VALIDITY OF FIVE FORMULAS TO ESTIMATE 24-HOUR
P. Iliakis (Athens, GREECE) URINARY SODIUM BY SPOT URINE SAMPLES IN ADULTS LIVING IN
NORTHEAST CHINA
15.30-15.40 Chronic kidney disease and aging - results from EHUH W. Song, N. Qian, R. Guo, Y. Zhang, Y. Jiang
and ENAH studies Dalian, CHINA
M. Matasin (Zagreb, CROATIA)
15.14 SYSTOLIC INTER-ARM BLOOD PRESSURE DIFFERENCE
15.40-15.50 Resistant hypertension - experience from two centers AND COGNITIVE DECLINE: FINDINGS FROM THE INTERPRESS-IPD
N. Radivojecic (Belgrade, SERBIA), A. Jelakovic (Zagreb, COLLABORATION
CROATIA) C. Clark 1, K. Boddy 1, F. Warren 1, S. Mcdonagh 1, S. Moore 1, V. Aboyans
2
, L. Cloutier 3, R. Mcmanus 4, A. Shore 1, R. Taylor 1,5, J. Campbell 1
15.50-16.00 How to establish national registry on fibromuscular 1
Exeter, UNITED KINGDOM, 2 Limoges, FRANCE, 3 Québec, CANADA,
dysplasia and join European/International registry 4
Oxford, 5 Glasgow, UNITED KINGDOM
Ž. Dika (Zagreb, CROATIA), M. Stojanovic (Belgrade,
SERBIA), M. Dorobantu (Bucharest, ROMANIA), 15.21 SYSTOLIC BLOOD PRESSURE IS A MAJOR COMPONENT
A. Triantafyllou (Thessaloniki, GREECE) OF THE RISK SCORE FOR NEW PROGRESSION OF CAROTID
PLAQUE: THE SUITA STUDY
Y. Kokubo, M. Watanabe, A. Higashiyama, K. Honda-Kohmo, Y. Miyamoto
Suita, JAPAN
16
15.00-16.00 - ROOM 5
15.28 ORTHOSTATIC BLOOD PRESSURE CHANGES
AND SUBCLINICAL MARKERS OF ATHEROSCLEROSIS IN ESH Working Group on Endocrine
NORMOTENSIVE ADULTS. RESULTS FROM A NATIONAL-
REPRESENTATIVE SURVEY Hypertension
O.F.G. Gheorghe Fronea 1, R. Darabont 1, C. Pop 2, M. Dorobantu 1 Chairpersons: P. Mulatero (Turin, ITALY),
1
Bucharest, 2 Baia Mare, ROMANIA J. Widimský jr. (Prague, CZECH REPUBLIC)
15.35 SODIUM ACETATE ATTENUATES MYOCARDIAL

TRIGLYCERIDE ACCUMULATION IN COMBINED ORAL 15.00-15.15 Novel mechanisms in the pathogenesis of primary
CONTRACEPTIVE-TREATED RATS BY SUPPRESSING ADENOSINE aldosteronism
DEAMINASE/XANTHINE OXIDASE-DEPENDENT PATHWAY T.A. Williams (Turin, ITALY)
T. Omolekulo, L. Aderemi Olatunji
Ilorin, NIGERIA 15.15-15.30 Molecular mechanisms responsible for familial
hyperkalemic hypertension
15.42 PREDICTIVE POWER OF 24-HOUR AMBULATORY X. Jeunemaitre (Paris, FRANCE)
PULSE PRESSURE AND ITS COMPONENTS FOR MORTALITY
AND CARDIOVASCULAR OUTCOMES IN 11,848 PARTICIPANTS 15.30-15.40 Medical therapy for primary aldosteronism: more than
RECRUITED FROM 13 POPULATIONS spironolactone and eplerenone?
B. Gavish 1, M. Bursztyn 1, W.-Y. Yang 2, L. Thijs 2, Z.-Y. Zhang 2, M. Doumas (Thessaloniki, GREECE)
J. Boggia 3, T. W. Hansen 4, K. Asayama 5, T. Ohkubo 5, M. Kikuya 5,
Y. Imai 5, K. Stolarz-Skrzypek 6, Y. Li 2, J.-G. Wang 7, E. Casiglia 8, 15.40-15.50 Has genetic testing a real positive impact on
S. Malyutina 9, J. Staessen 2 management and outcome of patients with
1
Jerusalem, ISRAEL, 2 Leuven, BELGIUM, 3 Montevideo, URUGUAY, pheochromocytoma?
4
Copenhagen, DENMARK, 5 Sendai, JAPAN, 6 Krakow, POLAND, L. Amar (Paris, FRANCE)
7
Shanghai, CHINA, 8 Padua, ITALY, 9 Novosibirsk, RUSSIA
15.49 SUBSTANTIAL CHANGES IN CARDIOVASCULAR HEALTH
OCCUR FROM ADOLESCENCE TO EMERGING ADULTHOOD
C. Park 1, H. Taylor 1, A. Rapala 1, S. Williams 1, S. Jones 1, L. Howe 2,
N. Chaturvedi 1, A. Hughes 1
1
London, 2 Bristol, UNITED KINGDOM
17
15.00-16.00 - ROOM 6
15.28 GENES ASSOCIATED WITH BLOOD PRESSURE TRAITS
Oral Session 1B SHOW CELL TYPE-SPECIFIC EXPRESSION AND CONTROL
MULTIPLE CAUSAL LINKS TO BLOOD PRESSURE
REGULATION IN THE HUMAN KIDNEY
GENETICS, GENOMICS, PROTEOMICS,
J. Eales 1, X. Jiang 1, X. Xu 1, S. Saluja 1, E. Cano-Gamez 2, S. Pramanik 1,
METABOLOMICS P. Bogdanski 3, W. Wystrychowski 4, J. Zywiec 5,
Chairpersons: F.J. Charchar (Ballarat, AUSTRALIA), E. Zukowska-Szczechowska 4, A. Woolf 1, P. Maffia 6, T. Guzik 6,
G. Ehret (Geneva, SWITZERLAND) N. Samani 7, F. Charchar 8, M. Tomaszewski 1
1
Manchester, 2 Cambridge, UNITED KINGDOM, 3 Poznan, 4 Katowice,
5
Zabrze, POLAND, 6 Glasgow, 7 Leicester, UNITED KINGDOM,
15.00 KIDNEY DNA METHYLATION AS A DRIVER OF HERITABLE 8
Ballarat, AUSTRALIA
PREDISPOSITION TO BLOOD PRESSURE AND HYPERTENSION
X. Xu 1, J. Eales 1, X. Jiang 1, H. Guo 1, N. Samani 2, F. Charchar 3, 15.35 LEFT VENTRICULAR MASS AND URINARY METABOLOMICS
M. Tomaszewski 1 IN YOUNG BLACK AND WHITE ADULTS: THE AFRICAN-PREDICT
1
Manchester, 2 Leicester, UNITED KINGDOM, 3 Victoria, AUSTRALIA STUDY
D. de Beer 1, C. McMels 1, A.E. Schutte 1, R. Louw 1, C. Delles 2,
15.07 CIRCULATING METABOLIC BIOMARKERS AS POTENTIAL R. Kruger 1
LEADS FOR GLOBAL PREVENTION OF RENAL DYSFUNCTION – A 1
Potchefstroom, SOUTH AFRICA, 2 Glasgow, UNITED KINGDOM
FLEMISH COHORT STUDY
Z.-Y. Zhang 1, V. Marrachelli 2, W.-Yi Yang 1, L. Thijs 1, D. Monleon 2, 15.42 LECTURE
P. Verhamme 1, J. Redón 2, J. Staessen 1 GENOMICS OF BLOOD PRESSURE IN TWENTIES
1
Leuven, BELGIUM, 2 Valencia, SPAIN M.J. Caulfield (London, UNITED KINGDOM)
15.14 PROTEOMIC ASSESSMENT OF CIRCULATING

MICROPARTICLES IN HYPERTENSION AND DIABETES
O. Varol, M. Turner, J.-F. Thibodeau, C. Holterman, C. Kennedy, D. Burger
Ottawa, CANADA
15.21 A NEW GENETIC RISK SCORE FOR BLOOD PRESSURE

STRONGLY ASSOCIATES WITH THE INCIDENCE OF
HYPERTENSION AND CARDIOVASCULAR ENDPOINTS IN TWO
SWEDISH COHORTS
A. Giontella 1, M. Sjögren 2, L. Lotta 3, J. Overton 3, A. Baras 3,
Regeneron Genetics Center 3, F. Cristiano 1, O. Melander 2
1
Verona, ITALY, 2 Malmö, SWEDEN, 3 Tarrytown, NY, USA
18
16.00-16.45 - AUDITORIUM 16.00-16.45 - ROOM 1
supported by Menarini Group supported by an unrestricted educational grant from AstraZeneca
HITTING THE BULL’S-EYE IN HYPERTENSION IMPROVING CARDIORENAL OUTCOMES IN

MANAGEMENT HYPERTENSION
Chairpersons: B. Williams (London, UNITED KINGDOM), Chairperson: J. McMurray (Glasgow, UNITED KINGDOM)
M. Volpe (Rome, ITALY)
16.00-16.10 CVD and CKD in diabetes and hypertension

16.00-16.15 Treatment strategies: Can we do something more? P. Rossing (Copenhagen, DENMARK)
16.10-16.25 From hypertension to kidney disease
16.15-16.35 Tailoring the treatment to each patient D. Wheeler (London, UNITED KINGDOM)
M. Volpe (Rome, ITALY)
16.25-16.40 Stopping the journey to cardiovascular disease
16.35-16.45 Q&A and closing remarks M. Kosiborod (Kansas City, MO, USA)
16.40-16.45 Q&A
19
16.00-16.45 - ROOM 2 16.00-17.00 - ROOM4
Minisymposium Late-Breakers Oral Session

supported by ReCor Medical Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM),
A REVIEW OF THE RADIANCE-HTN GLOBAL
CLINICAL TRIAL PROGRAM: RENAL
DENERVATION USING ULTRASOUND ABLATION 16.00 EFFECTS OF BLOOD PRESSURE-LOWERING ON CANCER
RISK: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF
Chairperson: R.E. Schmieder (Erlangen, GERMANY) 300,000 PARTICIPANTS
E. Copland 1, D. Canoy 1, M. Nazarzadeh 1, Z. Bidel 1, M. Woodward 3,4,5,
J. Chalmers 3, K. Teo 6, C. Pepine 7, B. Davis 8, S. Kjeldsen 9,
16.00-16.05 Session objectives J. Sundstrom 2, K. Rahimi 1
R.E. Schmieder (Erlangen, GERMANY)
1
Oxford, UNITED KINGDOM, 2 Uppsala, SWEDEN, 3 Sydney, AUSTRALIA,
4
London, UNITED KINGDOM, 5 Baltimore, MD, USA, 6 Hamilton, CANADA,
7
Gainesville, FL 8 Houston, TX, USA, 9 Oslo, NORWAY
16.05-16.15 Renal denervation using ultrasound: an overview,
history of the field, and potential benefits of the
16.07 THE ERYTHROCYTE MEMBRANES BETA
ultrasound approach ADRENOREACTIVITY CHANGES AFTER RENAL DENERVATION AS A
M. Lobo (London, UNITED KINGDOM) PROGNOSTIC FACTOR FOR THE LONG-TERM ANTIHYPERTENSIVE
EFFICACY OF THE INTERVENTION
16.15-16.30 RADIANCE-HTN SOLO: a review of study design and I. Zyubanova, A. Falkovskaya, V. Mordovin, M. Manukyan, S. Pekarskiy,
discussion of its primary analysis and outcomes V. Lichikaki, T. Rebrova, S. Afanasiev
M. Azizi (Paris, FRANCE) Tomsk, RUSSIA
16.30-16.40 RADIANCE-HTN TRIO: a review of study design and its 16.14 PROXIMAL TUBULE-SPECIFIC DELETION OF AT1A
significance RECEPTORS ATTENUATES CIRCULATING AND INTRATUBULAR
M. Azizi (Paris, FRANCE) ANGIOTENSIN II-INDUCED HYPERTENSION IN MICE
X. Li 1, A.P. Leite 1, X. Zheng 2, C. Zhao 2, L. Zhang 1, X. Chen 3, X. Zhou 3,
J. Zhuo 1
16.40-16.45 Session evaluation and key learnings 1
New Orleans, LA, USA, 2 Nanning, CHINA, 3 Jackson, MS, USA
R.E. Schmieder (Erlangen, GERMANY)
16.21 LONG TERM BENEFITS OF BLOOD PRESSURE TREATMENT
ON THE INCIDENCE OF ATRIAL FIBRILLATION, HEART FAILURE
AND CARDIOVASCULAR MORBIDITY AND MORTALITY: 20-YEARS
FOLLOW-UP OF ASCOT-LEGACY
A. Gupta 1, W. Whiteley 2, T. Godec 1, S. Rostamian 1, A. Whitehouse 1,
J. Mackay 1, P. Sever 1
1
London, 2 Edinburgh, UNITED KINGDOM
20
16.00-17.00 - ROOM 5
16.28 SAFETY, PHARMACODYNAMICS, AND BLOOD PRESSURE
EFFECTS OF ALN-AGT, AN RNA INTERFERENCE THERAPEUTIC
TARGETING ANGIOTENSINOGEN, IN A RANDOMIZED SINGLE
Oral Session 2A
ASCENDING DOSE STUDY OF HYPERTENSIVE ADULTS
S. A. Huang 1, J. Taubel 2, G. Fiore 3, P. Dewland 3, D.J. Webb 4, RESISTANT HYPERTENSION - INTERVENTIONAL
G.L. Bakris 5, A.S. Desai 6, Y. Cheng 1, S. Agarwal 1, J. Harrop 1, THERAPIES
H.V. Nguyen 1, J. Lu 1, D. Foster 1, K. Fujita 1
1
Cambridge, MA, USA, 2 London, 3 Manchester, 4 Edinburgh, UNITED Chairpersons: A. Prejbisz (Warsaw, POLAND),
KINGDOM, 5 Chicago, IL, 6 Boston, MA, USA M. Schlaich (Perth, AUSTRALIA)
16.35 BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE

TREATMENT, AND INCIDENT DIABETES 16.00 LECTURE
M.Nazarzadeh 1, Z. Bidel 1, D. Canoy 1, E. Copland 1, M. Wamil 1, TARGETING NEUROMODULATION FOR THE MANAGEMENT OF
K. Smith Byrne 1, J. Sundström 2, K. Teo 3, B.R. Davis 4, J. Chalmers 5, HYPERTENSION: DRUGS, DEVICES OR BOTH?
C.J. Pepine 6, A. Dehghan 7, D.A. Bennet 1, G.D. Smith 8, K. Rahimi 1
1
Oxford, UNITED KINGDOM, 2 Uppsala, SWEDEN, 3 Ontario, CANADA,
4
Texas, TX, USA, 5 Sydney, AUSTRALIA, 6 Florida, FL, USA, 7 London,
8
Bristol, UNITED KINGDOM 16.15 BLOOD PRESSURE EFFECTS OVER TIME OF BIPOLAR
RADIOFREQUENCY RENAL DENERVATION IN UNTREATED
16.42 SOMATIC MUTATIONS IN ADRENALS FROM PATIENTS HYPERTENSION
WITH PRIMARY ALDOSTERONISM NOT CURED AFTER M. Weber 1, A. Kirtane 2, M. Weir 3, M. Leon 2
ADRENALECTOMY SUGGEST COMMON PATHOGENIC 1
Brooklyn, NY, 2 New York, NY, 3 Baltimore, MD, USA
MECHANISMS BETWEEN UNILATERAL AND BILATERAL DISEASE
I. Hacini, K. De Sousa, S. Boulkroun, T. Meatchi, L. Amar, M.-C. Zennaro, 16.22 IMPACT OF SHAM PROCEDURE ON BLOOD PRESSURE
F.L. Fernandes-Rosa LEVELS IN PATIENTS WITH UNCONTROLLED HYPERTENSION:
Paris, FRANCE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF RENAL
DENERVATION TRIALS
16.49 SELF-MONITORING OF BLOOD PRESSURE IN WOMEN
WITH PREGNANCY HYPERTENSION: THE BUMP2 MULTICENTRE K. Stavropoulos 1, A. Katsimardou 1, K. Imprialos 1, D. Patoulias 1,
RANDOMISED CONTROLLED TRIAL K. Koutsampasopoulos 1, Z. Tegou 1, S. Alataki 1, S. Bouloukou 1,
L. Chappell 1, K. Tucker 2, L.-M. Yu 1, R. McManus 1 K. Dimitriadis 2, V. Papademetriou 3, K. Tsioufis 2, M. Doumas 1,3
1
Oxford, 2 London, UNITED KINGDOM 1
Thessaloniki 2 Athens, GREECE, 3 Washington, DC, USA
16.29 ANATOMY OF RENAL DENERVATION DURABILITY

A. Sharp 1, S. Tunev 2, M. Schlaich 3, D. Lee 4, A. Finn 5, R. Melder 2,
J. Trudel 2, D. Kandzari 6
1
Wales, UNITED KINGDOM, 2 Santa Rosa, CA, USA, 3 Perth, AUSTRALIA,
4
Stanford, CA, 5 Gaithersburg, MD, 6 Atlanta, GA, USA
21
16.00-17.00 - ROOM 6
16.36 CARDIOVASCULAR OUTCOMES AND ALL-CAUSE
MORTALITY ASSOCIATED WITH APPARENT TREATMENT- Oral Session 2B
RESISTANT HYPERTENSION APPLYING THE 2017 ACC/AHA
GUIDELINE
EPIDEMIOLOGY OF HYPERTENSION AND
A. Jaejin 1, J. Sim 2, R. Lui 1, H. Zhou 1, D. Calhoun 3, R. Wei 1, T. Luong 1,
K. Reynolds 1 METABOLIC DISORDERS
1
Pasadena, CA, 2 Los Angeles, CA, 3 Birmingham, AL, USA Chairpersons: N. Khan (Vancouver, CANADA),
D. Lovic (Niš, SERBIA)
16.43 ESTABLISHING SERUM REFERENCE RANGES OF
ANTIHYPERTENSIVE DRUGS
S. Rognstad 1 C. Lund Søraas 1, O. Undrum Bergland 1, A. Høieggen 1,2, 16.00 SELF-TESTING OF BLOOD PRESSURE ACCORDING TO THE
M. Strømmen 2, A. Helland 2, M. Stokke Opdal 1 DEPISTHTA® PROTOCOL IN THE POPULATION OF THE FRENCH
1
Oslo, 2 Trondheim, NORWAY LEAGUE AGAINST HYPERTENSION SURVEY 2019
X. Girerd, A. Pathak, B. Vaïsse, O. Hanon
16.50 PATIROMER VS PLACEBO TO ENABLE SPIRONOLACTONE Paris, FRANCE
IN PATIENTS WITH RESISTANT HYPERTENSION AND CKD:
ANALYSIS ACCORDING TO PATIENT SEX (AMBER TRIAL) 16.07 LACK OF FUNDING AND LONG-TERM JOB
B. Williams 1, W.B. White 2, M.R. Mayo 3, S. Warren 3, S. Arthur 3, SECURITY THREATENS TO HAVE PROFOUND EFFECTS ON
G. Ackourey 3, P. Rossignol 4, R. Agarwal 5 CARDIOVASCULAR RESEARCHER RETENTION IN AUSTRALIA
1
London, UNITED KINGDOM, 2 Farmington, CT, 3 Redwood City, CA, USA, F. Marques 1, R. Climie 1, J. Wu 2, A. Calkin 1, N. Chapman 3, K. Colafella 1,
4
Nancy, FRANCE, 5 Indianapolis, IN, USA D. Picone 3, H. Viola 4, A. Murphy 1, M. Nelson 3, S. Nichols 1, L. Hool 4,
G. Figtree 2
1
Melbourne, 2 Sydney, 3 Hobart, 4 Perth, AUSTRALIA
16.14 SUSTAINABILITY OF BLOOD PRESSURE REDUCTIONS AT

INTERVENTIONS LED AT BARBERSHOPS: SYSTEMATIC REVIEW
AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
A. Muruganathan 1, F. Rader 2, C. Blyler 2, K. Vijayaraghavan 3,
A. Maheshwari 4, N. Verma 4, M.R. Mubarak 5, M.K. Das 6, P.P. Mohanan 7,
S. Mishra 8, A. Mehta 8
1
Tirupur, INDIA, 2 Los Angeles, CA, 3 Phoenix, AZ, USA, 4 Lucknow, INDIA,
5
Colombo, SRI LANKA, 6 Kolkata, 7 Thrissur, 8 Delhi, INDIA
22
16.21 LONGITUDINAL CHANGE IN RENAL DYSFUNCTION

BIOMARKERS PREDICT OUTCOME DIFFERENTLY IN
HYPERTENSIVE AND NORMOTENSIVE PERSONS FROM THE
GENERAL POPULATION. THE TROMSØ STUDY
M. Dahl Solbu 1, T. Melsom 1, J. Viljar Norvik 1, B.O. Eriksen 1,
A.E. Eggen 1, M.-L. Løchen 1, S.N. Zykova 1,2, T.G. Jenssen 1,2
1
Tromsø, 2 Oslo, NORWAY
16.28 RENIN-ANGIOTENSIN SYSTEM INHIBITION,

CARDIORESPIRATORY FITNESS AND MORTALITY RISK IN
DIABETIC PATIENTS
A. Pittaras 1, H. Grassos 2, M. Doumas 2, J. Myers 2, C. Faselis 2,
P. Kokkinos 2
1
Athens, GREECE, 2 Washington, DC, USA
16.35 REMAINING CARDIOVASCULAR RISK MARKERS IN

PARTICIPANTS WITH WHITE-COAT HYPERTENSION DIAGNOSED
BY HOME BLOOD PRESSURE RECORDINGS
M. Johansson, E. Ström, C.J. Östgren, J. Engvall, M. Wijkman, F. Nyström
Linköping, SWEDEN
16.42 THE ASSOCIATION OF TESTOSTERONE IN UMBILICAL

CORD BLOOD AND SYSTOLIC BLOOD PRESSURE IN OFFSPRING
IN YOUNG ADULTHOOD
L. Beilin 1, C. Le-Ha 1, T. Mori 1, M. Hickey 2, J. Keelan 1, S. Burrows 1
1
Perth, 2 Melbourne, AUSTRALIA
16.49 SERUM CHLORIDE AND ADVERSE CARDIOVASCULAR RISK

IN THE WEST OF SCOTLAND GENERAL POPULATION
L. McCallum, S. Lip, S. Padmanabhan
Glasgow, UNITED KINGDOM
23
MONDAY, APRIL 12 SCIENTIFIC PROGRAMME
11.00-12.00 - AUDITORIUM 11.00-12.00 - ROOM 1
Topical Workshop on Hot Issues The Iberican Session

(ISH Session)
THE IBERICAN STUDY: ANALYSIS OF
HYPERTENSION IN PREGNANCY CARDIOVASCULAR RISK IN SPAIN
Chairpersons: L. Brewster (Amsterdam, THE NETHERLANDS), Chairpersons: A. Coca (Barcelona, SPAIN),
C. Siew Mooi (Seri Kembangan, MALAYSIA) J. Polo Garcia (Caceres, SPAIN)
11.00-11.12 Associations between pregnancy hypertensive 11.00-11.25 Relationship between hypertension and associated
disorders and common cardiovascular disorders: cardiovascular risk factors on cardiovascular prognosis
the CALIBER study in Spain
L. Chappell (Oxford, UNITED KINGDOM) J. Polo Garcia (Caceres, SPAIN)
11.12-11.24 Cardiovascular risk in women after preeclampsia/ 11.25-11.50 Cardiovascular risk and kidney disease in patients seen
hypertension in pregnancy: a link to microvascular by Primary Care physicians in Spain
dysfunction? R. Mico’ Pérez (Valencia, SPAIN)
R. Dechend (Berlin, GERMANY)
11.50-12.00 Conclusion and discussion
11.24-11.36 Peri-partum management of hypertension A. Coca (Barcelona, SPAIN)
R. Cifková (Prague, CZECH REPUBLIC)
11.36-11.48 Talk by the Winner of ISH Mid-Career Award for Women

F. Marques (Melbourne, AUSTRALIA)
26
11.00-12.00 - ROOM 2
ISH Hypertension Guidelines

THE ISH 2020 GLOBAL HYPERTENSION PRACTICE
GUIDELINES
SECTION 1 SECTION 2
Chairpersons: E. Ogola (Nairobi, KENYA), Chairpersons: Y. Kokubo (Suita, Osaka, JAPAN),
A. Schutte (Sydney, AUSTRALIA), A. Ramirez (Buenos Aires, ARGENTINA),
M.A. Weber (Brooklyn, NY, USA) R. Wainford (Boston, MA, USA)
11.00-11.05 Introduction 11.33-11.38 Common and uncommon comorbidities

A. Schutte (Sydney, AUSTRALIA) C. Borghi (Bologna, ITALY)
11.05-11.08 Process of writing 11.38-11.43 Secondary and resistant hypertension

T. Unger (Maastricht, THE NETHERLANDS) M. Tomaszewski (Manchester, UNITED KINGDOM)
11.08-11.13 Definition of hypertension and blood pressure 11.43-11.48 Pregnancy, emergencies and other issues
measurement N. Khan (Vancouver, CANADA)
G.S. Stergiou (Athens, GREECE)
11.48-11.53 Ethnic aspects
11.13-11.18 Diagnostics and HMOD D. Prabhakaran (Gurugram, INDIA)
11.53-11.58 Hypertension Guidelines at a glance
11.18-11.23 Lifestyle modifications T. Unger (Maastricht, THE NETHERLANDS)
F.J. Charchar (Ballarat, AUSTRALIA)
11.23-11.28 Optimal treatment standards
11.28-11.33 Essential treatment standards

N.R. Poulter (London, UNITED KINGDOM)
27
11.00-12.00 - ROOM 3 11.00-12.00 - ROOM 4
Joint Session ESH-ISH-KSH Oral Session 3A

IMPORTANCE OF AMBULATORY BLOOD PRESSURE EXPERIMENTAL HYPERTENSION AND
MONITORING IN CARDIOVASCULAR PHARMACOLOGY
PREVENTION Chairpersons: R.M. Bruno (Paris, FRANCE),
Chairpersons: P. Palatini (Padua, ITALY) M. Fernández-Alfonso (Madrid, SPAIN)
W.-B. Pyun (Seoul, SOUTH KOREA)
Panelist: H. Itoh (Tokyo, JAPAN)
11.00 LOW-DOSE FOLIC ACID PROTECTS AGAINST ADVERSE
CARDIAC REMODELING IN SPONTANEOUSLY HYPERTENSIVE
RATS WITH HYPERHOMOCYSTEINEMIA
11.00-11.15 24 hour blood pressure patterns in hypertensive
R. Xu 1, P. Cao 2
patients 1
Jinan, 2 Taian, CHINA
S.-H. Ihm (Bucheon, SOUTH KOREA)
11.07 AFFERENT PEPTIDERGIC NERVE FIBERS – IMPORTANCE
11.15-11.30 Changes of 24 hour blood pressure pattern after
FOR THE SALT METABOLISM BEYOND THE KIDNEYS?
antihypertensive medication
T. Ditting, K. Rodionova, P. Reeh, R. Schmieder, M. Schiffer, K. Amann,
J. Shin (Seoul, SOUTH KOREA)
C.R. Ott, R. Veelken
Erlangen, GERMANY
11.30-11.45 Role of ambulatory blood pressure monitoring in heart
failure patient
11.14 CONTROL OF ANTIHYPERTENSIVE EFFECT MEDIATED BY
M. Camafort (Barcelona, SPAIN)
SMALL INTERFERING RNA TARGETING ANGIOTENSINOGEN
E. Uijl 1, K.M. Mirabito Colafella 2, L. Ren 1, E. J. Hoorn 2, I. Zlatev 3,
J.B. Kim 3, S. Huang 3, L. Melton 3, D. Foster 3, A.H.J. Danser 1,

R. van Veghel 1, I. M. Garrelds 1
1
Rotterdam, THE NETHERLANDS, 2 Melbourne, AUSTRALIA,
3
Cambridge, MA, USA
11.21 HIGH FASTING BLOOD GLUCOSE LEVEL INCREASE RISK

OF HYPERTENSION INCIDENCE INDEPENDENT OF INSULIN
RESISTANCE IN JAPANESE: THE SAKU STUDY
Y. Tatsumi 1, K. Asayama 1, A. Morimoto 2, N. Sonoda 2, N. Miyamatsu 3,
Y. Ohno 4, Y. Miyamoto 4, S. Izawa 5, T. Ohkubo 1
1
Itabashi, 2 Habikino, 3 Otsu, 4 Suita, 5 Saku, JAPAN
28
11.00-12.00 - ROOM 5
11.28 CYB5R3 BIASES SOLUBLE GUANYLYL CYCLASE
ACTIVATION IN RESISTANCE ARTERIES Oral Session 3B
B. Durgin, S. Hahn, A. Straub
Pittsburgh, PA, USA
MICROCIRCULATION AND SMALL VESSELS
11.35 HYPOTENSIVE EFFECTIVENESS OF THE INTRARENAL Chairpersons: M. Dorobantu (Bucharest, ROMANIA),
MEDULLARY ENDOTHELIN ETA RECEPTOR BLOCKADE IN THE R.M. Touyz (Glasgow, UNITED KINGDOM)
TWO ANIMAL MODELS OF HYPERTENSION
B. Badzynska 1, J. Sadowski 1, I. Vaneckova 2,
E. Kompanowska-Jezierska 1 11.00 INFLUENCE OF RENAL FUNCTION ON RETINAL VASCULAR
1
Warsaw, POLAND, 2 Prague, CZECH REPUBLIC DENSITY ASSESSED BY OCT ANGIOGRAPHY IN HYPERTENSIVE
PATIENTS
11.42 NOX4 PROTECTIVE EFFECT IN ENDOTHELIAL FUNCTION G. Mulè, M. Vadalà, G. Guarrasi, L. Guarino, M. Castellucci, A. Sorce,
INVOLVES ACTIVATION OF TRANSIENT RECEPTOR POTENTIAL R. Dell’Utri, A. Ferotti, S. Cillino, S. Cottone
MELASTATIN 2 (TRPM2) CATION CHANNEL Palermo, ITALY
R. Alves-Lopes, K. Neves, A. Montezano, R. Touyz
Glasgow, UNITED KINGDOM 11.07 NOX5 AND VASCULAR SIGNALLING IN HUMAN
HYPERTENSION
11.49 INTROGRESSION OF A BROWN NORWAY CHROMOSOME 2 L. Camargo 1, A. Montezano 1, M. Hussain 2, Y. Wang 1, Z. Zou 1, F. Rios 1,
FRAGMENT INTO DAHL SALT-SENSITIVE RATS EXERTS ANTI- AND F. Awan 2, R. Touyz 1
PRO-INFLAMMATORY EFFECTS UNDER A NORMAL AND HIGH- 1
Glasgow, UNITED KINGDOM, 2 Faisalabad, PAKISTAN
SALT DIET, RESPECTIVELY
O. Berillo 1, S. Ouerd 1, A. Rehman 1, C. Richer 1, D. Sinnett 1, A.E. Kwitek 2, 11.14 ROLE OF INHIBITION OF CGMP-DEPENDENT PROTEIN
P. Paradis 1, E.L. Schiffrin 1 KINASE (PKG) SIGNALLING ON ANTICONTRACTILE FUNCTION OF
1
Montreal, CANADA, 2 Milwaukee, WI, USA PERIVASCULAR ADIPOSE TISSUE
C. Agabiti Rosei, C. Rossini, C. De Ciuceis, E. Porteri, V. Brami, M. Nardin,
G. Chiarini, A. Petelca, M.A. Coschignano, G. A. Tiberio, M.L. Muiesan,
D. Rizzoni
Brescia, ITALY
11.21 ROSTAFUROXIN RESTORES THE INCREASED

PERIVASCULAR INNERVATION IN RESISTANCE ARTERIES OF
HYPERTENSIVE RATS
R.B. de Paula, L. Venturini Rossoni
São Paulo, BRAZIL
29
11.00-12.00 - ROOM 6
11.28 STRUCTURAL ALTERATIONS OF MICROCIRCULATION IN
CANCER PATIENTS TREATED WITH ANTIANGIOGENIC DRUGS Workshop
V. Brami, M. A. Coschignano, C. De Ciuceis, C. Rossini, A. Berruti,
C. Agabiti Rosei, A. Paini, D. Cosentini, A. Dalla Volta, M. Salvetti,
HYPERTROPHY OF THE HEART - THE KEY/CENTRAL
E. Porteri, A. Petelca, M. Nardi, G. Chiarini, M.L. Muiesan, D. Rizzoni
Brescia, ITALY HMOD REVISITED
Chairpersons: T. de Backer (Ghent, BELGIUM),
11.35 RELATIONSHIPS BETWEEN CHOROIDAL THICKNESS AND A.M. Heagerty (Manchester, UNITED KINGDOM)
24H PULSE PRESSURE IN HYPERTENSIVE PATIENTS
G. Mulè, M. Vadala, G. Guarrasi, A. Sorce, K. Montalbano, C. Carollo,
E. Mancia, S. Cottone 11.00-11.20 Left ventricular hypertrophy (LVH) is a key prognostic
Palermo, ITALY indicator in hypertension. Diagnosis and mechanisms
E. Agabiti Rosei (Brescia, ITALY)
11.42 LECTURE
THE ANGIOTENSIN AT2-RECEPTOR: NEW INSIGHTS INTO ITS 11.20-11.40 The role of LVH as the key Hypertension Mediated
NATURE AND INTO CLINICAL DEVELOPMENT Organ Damage (HMOD) in the European Hypertension
U.M. Steckelings (Odense, DENMARK) Guidelines revisited. Regression of LVH during
treatment and less cardiovascular complications
S.E. Kjeldsen (Oslo, NORWAY)
11.40-12.00 Panel Discussion
30
Plenary Session Satellite Symposium

Chairpersons: A. Januszewicz (Warsaw, POLAND), supported by Servier
R. Kreutz (Berlin, GERMANY),
E. Lurbe (Valencia, SPAIN), IMPROVING THE MANAGEMENT OF HYPERTENSION:
K. Tsioufis (Athens, GREECE) ACTING ON KEY FACTORS
Chairpersons: R. Kreutz (Berlin, GERMANY) ,
A. Pathak (Monaco, MONACO)
12.00-12.30 Presentation of ESH Awards
Björn Folkow Award
M. Schlaich (Perth, AUSTRALIA) 13.00-13.05 Introduction
Alberto Zanchetti Life Achievement Award
P. Palatini (Padua, ITALY) 13.05-13.15 How to improve awareness and diagnosis
ESH Honorary Membership N.R. Poulter (London, UNITED KINGDOM)
P. Whelton (New Orleans, LA, USA)
13.15-13.45 How to tackle therapeutic inertia and improve treatment
Peter A. van Zwieten Award adherence
M. Volpe (Rome, ITALY) M. Burnier (Lausanne, SWITZERLAND),
M. Kavanagh (Wicklow, IRELAND),
Servier Research Grant in Hypertension
R. Boulestreau (Pau, FRANCE)
Talal Zein Award 13.45-14.00 Discussion and conlcusion
R. Alves-Lopes (Glasgow, UNITED KINGDOM)
J.-J. Mourad (Paris, FRANCE)
P. Palatini (Padua, ITALY)
E. Rodilla Sala (Valencia, SPAIN)
S.Toupance (Nancy, FRANCE)
Z.-Y. Zhang (Leuven, BELGIUM)

12.30-12.40 Presidential Lecture

12.40-13.00 Björn Folkow Award Lecture
31
13.00-14.00 - ROOM 1 13.00-14.00 - ROOM 2
Teaching Seminar Oral Session 4A

SESSION 1 CEREBROVASCULAR DISEASE, STROKE AND
Chairpersons: D.L. Clement (Ghent, BELGIUM), COGNITIVE DYSFUNCTION
A.F. Dominiczak (Glasgow, UNITED KINGDOM) Chairpersons: P. Cunha (Guimarães, PORTUGAL),
U. Martin (Birmingham, UNITED KINGDOM)
13.00-13.12 Place of total risk calculation in the management of

hypertension 13.00 LECTURE
T. de Backer (Ghent, BELGIUM) HYPERTENSION, SALT AND DEMENTIA: TOWARDS A MOLECULAR
UNDERSTANDING
13.12-13.24 Genes and hypertension: advances ready for C. Iadecola (New York, NY, USA)
application in practice?
S. Padmanabhan (Glasgow, UNITED KINGDOM) 13.15 THE STUDY ON THE CARDIAC AND VASCULAR
CHARACTERISTICS AND THEIR RELATIONSHIPS TO THE
13.24-13.36 Do we need to explore the coronary circulation in all COGNITIVE FUNCTION IN PERIMENOPAUSAL WOMEN WITH
hypertensive patients? HYPERTENSION
K. Tsioufis (Athens, GREECE) H. Shi, J. Yu
Lanzhou, CHINA
13.36-13.48 Cardiovascular effects of anti-cancer drugs
N. Lang (Glasgow, UNITED KINGDOM) 13.22 HYPERTENSION, AUTONOMIC DYSFUNCTION AND
SUDDEN DEATH RISK IN CADASIL DISEASE: NOVEL DATA
13.48-14.00 Discussion C. Kotliar, S. Obregon
Buenos Aires, ARGENTINA
13.29 HYPERCOG COGNITIVE SCREENING IN OLDER ADULTS

WITH HYPERTENSION: A PILOT STUDY
M.F. D’Andria, G. Rivasi, G. Turrin, V. Tortù, D. Falzone, E. Giuliani,
A. Giordano, A. Ungar
Florence, ITALY
32
13.00-14.00 - ROOM 3
13.36 POPULATION ATTRIBUTABLE FRACTION OF
HYPERTENSION FOR ONSET OF ISCHEMIC STROKE AMONG Oral Session 4B
ATRIAL FIBRILLATION PATIENTS WITH AND WITHOUT
ANTICOAGULATION
DIABETES
T. Maeda, T. Nishi, S. Funakoshi, K. Tada, M. Tsuji, A. Satoh, M. Kawazoe,
C. Yoshimura, H. Arima Chairpersons: D. Burger (Ottawa, CANADA),
Fukuoka, JAPAN V. Kotsis (Thessaloniki, GREECE)
13.43 DONEPEZIL IMPROVES VASCULAR FUNCTION IN A MOUSE

MODEL OF ALZHEIMER’S DISEASE 13.00 IMPACT OF HYPERTENSION IN THE MORBIDITY AND
S. Masi, L. Antonioli, E. Duranti, M. Fornai, C. Pellegrini, F. Baldacci, MORTALITY IN DIABETES MELLITUS: A REAL-WORLD DATA
S. Taddei, C. Blandizzi, A. Virdis I. Sauri, R. Uso, J. L. Trillo, A. Fernandez, J.L. Holgado, C. Lopez, S. Vela,
Pisa, ITALY C. Bea, A. Ruiz, F- Martinez, J. Redon
Valencia, SPAIN
13.50 NEW STROKE RISK SCORE FOR PATIENTS WITH
CORONARY ARTERY DISEASE 13.07 PREDIABETES AND RISKS FOR ALL-CAUSE AND
L. Minushkina 1, V. Brazhnik 1, E. Zubova 1, M. Chichkova, N. Hasanov 2, CARDIOVASCULAR MORTALITY BY HYPERTENSION STATUS:
E. Kosmacheva 3, D. Zateyshchikov 1 RESULTS FROM THE NATIONAL HEALTH AND NUTRITION
1
Moscow, 2 Kazan, 3 Krasnodar, RUSSIA EXAMINATION SURVEYS
L. Liu 1, Y. Huang 1, J. Huang 1, C. Chen 1, Y. Yu 1, G. Shen 1, K. Lo 1,2,
Y. Feng 1
1
Guangzhou, CHINA, 2 Providence, RI, USA
13.14 ARTERIAL STIFFNESS IMPROVEMENT IN HYPERTENSIVE

TYPE 2 DIABETIC PATIENTS: DISSIMILAR EFFECTS OF
CANAGLIFLOZIN AND PERINDOPRIL
A.J. Ramirez, M.J. Sanchez, R.A. Sanchez
13.21 EFFECTS OF DAPAGLIFLOZIN IN HIGH AND LOW DIETARY

SALT INTAKE PATIENTS WITH ALBUMINURIC DIABETIC KIDNEY
DISEASE: A SUBANALYSIS OF THE Y-AIDA STUDY
S. Kinguchi, H. Wakui, T. Misumi, K. Azushima, T. Yamanaka, Y. Terauchi,
K. Tamura
Yokohama, JAPAN
33
13.00-14.00 - ROOM 5
13.28 MODULATION OF SYMPATHETIC NERVE ACTIVITY BY
SGLT2 INHIBITOR EMPAGLIFLOZIN IN DIABETIC RABBITS Oral Session 4C
C. Gueguen 1, S.L. Burke 1, B. Barzel 1, K. Lim 1, N. Eikelis 1, A. Watson 1,
J.C. Jha 1, K.L. Jackson 1, Y. Sata 1, G.W. Lambert 1, K. Jandeleit-Dahm 1,2,
PREGNANCY
M.E. Cooper 1, M.C. Thomas 1, G.A. Head 1
1
Melbourne, AUSTRALIA, 2 Düsseldorf, GERMANY Chairpersons: R. Cifková (Prague, CZECH REPUBLIC),
T. Unger (Maastricht, THE NETHERLANDS)
13.35 PREDIABETES, PREHYPERTENSION AND RISK FOR
ALL-CAUSE AND CARDIOVASCULAR MORTALITY AMONG US
ADULTS: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION 13.00 SODIUM ACETATE AND EPLERENONE RESTORE RENAL
EXAMINATION SURVEYS GLUTATHIONE AND ADENOSINE CONTENT OF RATS EXPOSED TO
C.-L. Chen 1, L. Liu 1, J.-Y. Huang 1, Y.-L. Yu 1, G. Shen 1, K. Lo 2, TESTOSTERONE DURING LATE GESTATION
Y.-Q. Huang 1, Y.-Q. Feng 1 T. Usman 1, O. Adeyanju 2, E. Areola 3, O. Badmus 4, K. Olaniyi 2,
1
Guangzhou, CHINA, 2 Providence, RI, USA I. Oyeyipo 1, L. Olatunji 3
1
Osogbo, 2 Ado-Ekiti, 3 Malete, 4 Ilorin, NIGERIA
13.42 THE EFFECT OF DAPAGLIFLOZIN ON 24-HOUR BLOOD
PRESSURE AND ARTERIAL STIFFNESS IN PATIENTS WITH TYPE-2 13.07 PREVALENCE OF CHRONIC HYPERTENSION IN PREGNANT
DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL WOMEN FOLLOWING THE 2017 ACC/AHA GUIDELINE CHANGE IN
TRIAL DIAGNOSTIC CRITERIA FOR HYPERTENSION
E. Papadopoulou, C. Loutradis, G. Tzatzagou, K. Kotsa, I. Zografou, K. Reynolds 1, H. Zhou 1, Z. Bider-Canfield 1, T.C. Cheetham 2, C. Portugal 1,
I. Minopoulou, M. Theodorakopoulou, A. Tsapas, A. Karagiannis, N.A. Bello 3
P. Sarafidis 1
Pasadena, CA, 2 Irvine,CA, 3 New York, NY, USA
Thessaloniki, GREECE
13.14 NOVEL MIRNAS AS TARGETS OF MESENCHYMAL STEM
13.49 SATURATED FATTY ACIDS IN ERYTHROCYTE MEMBRANES CELLS-BASED THERAPY FOR TREATMENT OF PREECLAMPSIA
IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS A. Alqudah 1, S. Suvakov 2, C. Richards 3, N. Todd 1, K.-A. Eastwood 1,
D. Marcon, A. Tagetti, A. Giontella, G. Monamì, L. Branz, S. Bortolotti, A.J. Hunter 1, V.A. Holmes 1, D.R. McCance 1, I.S. Young 1, F. Furlong 1,
C. Piona, A. Morandi, L. Trento, P. Minuz, C. Maffeis, C. Fava A. Ali 1, A. Krasnodembskaya 1, G. Lopez-Campos 1, V.D. Garovic 2,
Verona, ITALY L. McClements 1,3
1
Belfast, UNITED KINGDOM, 2 Rochester, USA, 3 Sydney, AUSTRALIA
13.21 PARAMETERS OF CHANGING COAGULATION SYSTEM IN

PREGNANT WOMEN WITH PREECLAMPSIA
B. Kurbanov
Tashkent, UZBEKISTAN
34
13.00-14.00 - ROOM 6
13.28 ATTENUATION OF PLACENTAL LIPID DEPOSITION BY
GLUTAMINE SUPPLEMENTATION IMPROVES FETAL OUTCOME IN ISH Regional Advisory Group - South and
INSULIN-RESISTANT PREGNANT RATS
K. Olaniyi 1, L. Olatunji 2 Central Asia
1
Ado-Ekiti, 2 Ilorin, NIGERIA Chairpersons: M. Ishaq (Karachi, PAKISTAN),
M.-C. Cho (Cheongju, SOUTH KOREA)
13.35 THE IMPORTANCE OF B2 CELLS IN THE HYPERTENSION
AND PATHOPHYSIOLOGY OF PLACENTAL ISCHEMIA DURING
PREGNANCY 13.00-13.05 ISH (SACA) RAG introduction and objectives
B. Lamarca, O. Herrock, S. Fitzgerald, J. Lemon, E. Deer, T. Ibrahim, M. Ishaq (Karachi, PAKISTAN)
N. Campbell, L. Amaral
Jackson, MS, USA 13.05-13.20 High blood pressure and its determinants among rural
adults of Bangladesh: baseline findings of WHO PEN
13.42 LOW DOSE SPIRONOLACTONE PROTECTS implementation
EXPERIMENTALLY-INDUCED POLYCYSTIC OVARIAN SYNDROME L. Barua (Dhaka, BANGLADESH)
FROM INSULIN-RESISTANT METABOLIC DISTURBANCES
O. Adeyanju, T. Falodun 13.20-13.35 Education in hypertension in South and Central Asia:
Ado-Ekiti, NIGERIA opportunities and challenges
M. Patil (Pune, INDIA)
13.49 MODULATION OF ANGIOGENIC BALANCE DURING
PREGNANCY BY EXOGENOUS HEPARIN 13.35-13.50 Insights from the Pakistan hypertension league
K. Moore, H. Chapman, E. George M. Ishaq (Karachi, PAKISTAN)
Jackson, MS, USA
35
14.00-14.45 - AUDITORIUM 14.00-14.45 - ROOM 1
supported by Omron Healthcare supported by Vifor Pharma
HOME BLOOD PRESSURE-GUIDED MANAGEMENT ENABLING RAASI THERAPY THROUGH LONG TERM
OF HYPERTENSION POTASSIUM CONTROL IN PATIENTS WITH
Chairperson: B. Williams (London, UNITED KINGDOM) THE HIGHEST UNMET NEED
Chairperson: J. Cleland (Glasgow, UNITED KINGDOM)
14.00-14.10 Opening remarks and Keynote speech

B. Williams (London, UNITED KINGDOM) 14.00-14.05 Welcome and Introduction
J. Cleland (Glasgow, UNITED KINGDOM)
14.10-14.25 Home blood pressure monitoring - its advantages and
future perspectives 14.05-14.15 Optimising RAAS inhibition-benefits for patients with
B. Williams (London, UNITED KINGDOM) the highest unmet need
14.25-14.40 Telemonitoring and self-management in the control of
hypertension 14.15-14.35 Evolving role of novel potassium binders in cardiorenal
R. McManus (Oxford, UNITED KINGDOM) medicine - overcoming barriers to enable sustained
renin-angiotensin-aldosterone system inhibitor therapy
14.40-14.45 Discussion Q&A M. Epstein (Miami, FL, USA)
14.35-14.45 Panel discussion & summary

36
14.00-14.45 - ROOM 2 14.00-15.00 - ROOM 3
Minisymposium Joint Session ESH-ISH-ESC

supported by Abbott
ON THE CROSSROAD BETWEEN HYPERTENSION
LET’S GET IT STRAIGHT - THE ROLE OF TARGETING AND CARDIOLOGY
CENTRAL SYMPATHETIC OUTFLOW IN Chairpersons: T. Kahan (Stockholm, SWEDEN),
HYPERTENSION K. Tsioufis (Athens, GREECE)
Chairperson: M. Schlaich (Perth, AUSTRALIA)
14.00-14.15 Patterns of acute and protracted cardiac injury in
14.00-14.12 The sympathetic nervous system - a key regulator of Covid-19
cardiovascular and metabolic control G. De Simone (Naples, ITALY)
P. Valensi (Paris, FRANCE)
14.15-14.30 Treatment of hypertension in patients with HFpEF:
14.12-14.24 Clinical relevance of targeting sympathetic overactivity current views and controversies
in cardiometabolic disease A. Kasiakogias (Athens, GREECE)
14.30-14.45 Blood pressure monitoring and control in patients with
14.24-14.36 Selective imidazoline receptor agonists (SIRAs) - real atrial fibrillation
world experience G.S. Stergiou (Athens, GREECE)
N. Zvartau (Saint-Petersburg, RUSSIA)
14.36-14.45 Panel Discussion/Q&A
37
14.00-15.00 - ROOM 4 14.00-15.00 - ROOM 5
Workshop Oral Session 5A

CERTIFICATE COURSE IN MANAGEMENT OF GLOBAL CVD
HYPERTENSION: A NOVEL CAPACITY BUILDING Chairpersons: T. Jafar (Singapore, SINGAPORE),
INITIATIVE G. Mancia (Milan, ITALY)
Chairpersons: N.R. Poulter (London, UNITED KINGDOM),
14.00 LECTURE
HYPERTENSION CONTROL IN THE SDG ERA
K.S. Reddy (New Delhi, INDIA)
14.00-14.20 Pace setter talk: Tackling hypertension in LMICs
through capacity building
14.15 ALCOHOL – THE MYTH OF CARDIOVASCULAR
D. Prabhakaran (Gurugram, INDIA)
PROTECTION
R. Schutte 1, G. Wannamethee 2
14.20-14.30 Certificate Course in Management of Hypertension - 1
Chelmsford, 2 London, UNITED KINGDOM
the journey so far - India and beyond
P.A. Jose (Gurugram, INDIA) 14.22 MISMATCH BETWEEN AVAILABLE CAPACITY AND
ESTIMATED NUMBER OF PHYSICIAN VISITS NEEDED FOR
14.30-14.39 Adoption and expansion - the PASCAR and Sudan HYPERTENSION CARE: AN ANALYSIS OF WORLDWIDE DATA
experience D. Neupane, Y. Gao, Y. Feng, K. Matsushita, L.J. Appel
E. Ogola (Nairobi, KENYA) Baltimore, MD, USA
14.39-14.48 Improving access through e-learning - e-CCMH 14.29 SODIUM INTAKE, LIFE EXPECTANCY AND ALL-CAUSE
initiative MORTALITY
M. Turner (Dallas, TX, USA) F. Messerli 1,2,3, L. Hoftetter 1, L. Syrogiannouli 1, E. Rexhaj 1, G. Siontis 1,
C. Seiler 1, S. Bangalore 3
14.48-15.00 Q&A session 1
Bern, SWITZERLAND, 2 Krakow, POLAND, 3 New York, NY, USA
14.36 AFTER 20 YEARS OF SUSTAINED REDUCTION, RECENT

TRENDS IN CARDIOVASCULAR DISEASE BURDEN HAVE
STAGNATED OR REVERSED TO INCREASE IN THE REGION OF
THE AMERICAS
R. Martinez 1, P. Soliz 1, O. Mujica 1, L. Reveiz 1, A. Moran 2, N. Campbell 3,
P. Ordunez 1
1
Washington DC, 2 New York, NY, USA, 3 Alberta, CANADA
38
14.00-15.00 - ROOM 6
14.43 THE ASSOCIATIONS BETWEEN HYPERTENSION AND
STROKE FROM MAY MEASUREMENT MONTH AND BETWEEN ISH Austin Doyle Award Session
NATIONAL HYPERTENSION PARAMETERS WITH STROKE
MORTALITY FROM THE GLOBAL BURDEN OF DISEASE Chairpersons: N. Jessen (Maputo, MOZAMBIQUE),
Q. Lin, T. Ye, T. Beaney, N. R. Poulter C. Mills (Reading, UNITED KINGDOM)
London, UNITED KINGDOM
14.00 STUDY ON REDUCTION OF MICROALBUMINURIA
14.50 FEASIBILITY AND ACCEPTABILITY OF A NOVEL AMONGST HYPERTENSIVE PATIENTS WITH USE OF TRIPLE
INTEGRATION OF ABSOLUTE CARDIOVASCULAR DISEASE RISK COMBINATION THERAPY (TRIPLIXAM)
ASSESSMENT INTO ROUTINE BLOOD CHOLESTEROL TESTING A. Arun
N. Chapman, R. Fonseca, L. Murfett, K. Beazley, R. McWhirter, Lucknow, INDIA
M. Schultz, M. Nelson, J. Sharman
14.12 CHARACTERIZATION OF GLUCOSE UPTAKE METABOLISM
Hobart, AUSTRALIA
IN VISCERAL FAT BY 18F-FDG PET/CT REFLECTS INFLAMMATORY
STATUS IN METABOLIC SYNDROME
K. Pahk, E. J. Kim, Y.-J. Lee, S. Kim, H. Seog Seo
Seoul, SOUTH KOREA
14.24 CENTRAL SYSTOLIC BLOOD PRESSURE RELATES

INVERSELY TO NITRIC OXIDE SYNTHESIS IN YOUNG BLACK
ADULTS: THE AFRICAN-PREDICT STUDY
A. Craig 1, C. Mc Mels 1, D. Tsikas 2, R.H. Boeger 3, E. Schwedhelm 3,
A.E. Schutte 1, R. Kruger 1
1
Potchefstroom, SOUTH AFRICA, 2 Hannover, 3 Hamburg, GERMANY
14.36 IMPLEMENTATION OF THE NOVEL HYPERTENSION-

SPECIFIC PATIENT-REPORTED OUTCOME MEASURE IN M-HEALTH.
A SINGLE-CENTRE EXPERIENCE
M. Ionov, E. Dubinina, N. Khromov-Borisov, I. Tregubenko, D. Kurapeev,
N. Zvartau, A. Konradi
Saint-Petersburg, RUSSIA
14.48 INTERACTION BETWEEN TRPM7 AND EPIDERMAL

GROWTH FACTOR RECEPTOR MEDIATES VASCULAR SMOOTH
MUSCLE CELL ACTIVATION AND PROLIFERATION
Z. Zou 1, F. Rios 1, K.B. Neves 1, R. Alves-Lopes 1, J. Ling 1, G. Baillie 1,
L.L. Camargo 1, T. Gudermann, V. Chubanov 2, A.C. Montezano 1,
R.M. Touyz 1
1
Glasgow, UNITED KINGDOM, 2 Munich, GERMANY
39
15.00-15.45 - AUDITORIUM 15.00-16.00 - ROOM 1
Minisymposium Oral Session 6A

supported by Servier
KIDNEY
STATINS IN HYPERTENSIVE PATIENTS: WHEN, WHY, Chairpersons: Y. Kokubo (Suita-Osaka, JAPAN),
HOW P. Sarafidis (Thessaloniki, GREECE)
Chairpersons: C. Borghi (Bologna, ITALY),
15.00 METABOLIC EFFECT OF A MINERALOCORTICOID
RECEPTOR ANTAGONIST IN A NEW MODEL OF DIABETIC
15.00-15.05 Introduction NEPHROPATHY
C. Borghi (Bologna, ITALY) R. Palacios, B. Bonnard, I. Lima-Posada, M. Genty, F. Jaisser
Paris, FRANCE
15.05-15.25 When to use statins in the management of hypertensive
patients 15.07 RETURN OF NERVE FUNCTION FOLLOWING RENAL
B. Williams (London, UNITED KINGDOM), DENERVATION IN THE PRESENCE OF ANGIOTENSIN-CONVERTING
J. Wolf (Gdansk, POLAND) ENZYME INHIBITION IN SPONTANEOUSLY HYPERTENSIVE RATS
S. Walton, H. Parkington, E. Kwok, K. Denton
15.25-15.35 Combined approach to improving blood pressure and Melbourne, AUSTRALIA
LDL-C control
C. Borghi (Bologna, ITALY) 15.14 VISIT-TO-VISIT GLOMERULAR FILTRATION RATE
VARIABILITY AS A PREDICTOR FOR CARDIOVASCULAR AND
15.35-15.45 Discussion and conclusion RENAL OUTCOMES IN ESSENTIAL HYPERTENSION: DATA FROM
A GREEK 8-YEAR-FOLLOW-UP STUDY
A. Laina, K. Tsioufis, K. Dimitriadis, A. Kasiakogias, I. Liatakis, E. Koutra,
I. Leontsinis, D. Konstantinidis, M. Kouremeti, E. Dri, P. Iliakis,
N. Vogiatzakis, K. Thomopoulos, D. Tousoulis
Athens, GREECE
15.21 PENDRIN REDUCTION IS ASSOCIATED WITH ACUTE

INTRAVENOUS SODIUM CHLORIDE LOADING IN PATIENTS WITH
PRIMARY ALDOSTERONISM
A. Wu 1, M.J. Wolley 1, Q. Wu 2, D. Cowley 1, R.D. Gordon 1, R.A. Fenton 2,
M. Stowasser 1
1
Brisbane, AUSTRALIA, 2 Aarhus, DENMARK
40
15.00-15.45 - ROOM 2
15.28 RENAL OXIDATIVE STRESS IN A MODEL OF
HYPERTENSION INDUCED BY SALINE OVERLOAD: ROLE OF Minisymposium
CHLORIDE ANION
supported by ReCor Medical
A.M. Puyó 1, N.M. Kouyoumdzian 2, P.D. Prince 2, G.D. Robbesaul 2,
G. Kim 2, M. Pandolfo 2, B.E. Fernández 2, M.L. Galleano 2, M.R. Choi 1,2
1
Buenos Aires, 2 Caba, ARGENTINA WHICH PATIENTS SHOULD BE CONSIDERED FOR
ULTRASOUND RDN AND HOW TO BUILD AN
15.35 TUBULOINTERSTITIAL INJURY WAS SUPPRESSED BY INTERVENTIONAL HYPERTENSION MANAGEMENT
INHIBITION OF PLATELET-DERIVED GROWTH FACTOR PATHWAY IN PRACTICE
RAT RENAL VENOUS CONGESTION MODEL
T. Hirose, T. Matsuki, C. Takahashi, I. Oba-Yabana, T. Kato, R. Tajima, Chairperson: G. Parati (Milan, ITALY)
T. Seki, S. Kinugasa, H. Nakamura, J. Tani, T. Mori
Sendai, JAPAN
15.00-15.05 Session objectives
15.42 RENAL FUNCTIONAL RESERVE IS RELATED TO THE G. Parati (Milan, ITALY)
NON-DIPPING PHENOTYPE AND TO THE EXERCISE HEART RATE
RESPONSE IN PATIENTS WITH ESSENTIAL HYPERTESION AND A 15.05-15.15 State of RDN today and recent clinical developments
PRESERVED RENAL FUNCTION M. Schlaich (Perth, AUSTRALIA)
K. Damianaki 1, M. Burnier 2, K. Tsioufis 1, K. Dimitriadis 1, D. Vlahakos 1,
D. Petras 1 15.15-15.30 What do referring physicians need to know: patient
1
Athens, GREECE, 2 Lausanne, SWITZERLAND screening, patient preference
J. Weil (Lubeck, GERMANY)
15.49 INITIAL EGFR DECLINE AND LONG-TERM RENAL
FUNCTION DURING BLOOD PRESSURE LOWERING THERAPY: A 15.30-15.40 Review of consensus statements and guidelines: what
PATIENT LEVEL META-ANALYSIS OF THE SPRINT AND ACCORD-BP is needed next?
RANDOMIZED CONTROLLED TRIALS K. Tsioufis (Athens, GREECE)
D. Collard, T. Brouwer, R. O. Engberink, A. Zwinderman, L. Vogt,
B.-J. van den Born 15.40-15.45 Session evaluation and key learnings
Amsterdam, THE NETHERLANDS G. Parati (Milan, ITALY)
41
15.00-16.00 - ROOM 3 15.00-16.00 - ROOM 4
How-to Session Topical Workshop

FIBROMUSCULAR DYSPLASIA (FMD), A HYPERTENSION IN CHILDREN AND ADOLESCENTS:
MULTIFACETED SYSTEMIC ARTERIAL DISEASE FROM PRIMORDIAL PREVENTION TO
Chairpersons: P. Boutouyrie (Paris, FRANCE), ADVANCED ASSESSMENT
D. Gasecki (Gdansk, POLAND) Chairpersons: A. Coca (Barcelona, SPAIN),
B. Falkner (Philadelphia, PA, USA)
15.00-15.15 Screening, diagnosis and management of renal artery

FMD 15.00-15.12 Impact of maternal health and fetal programming
A. Januszewicz (Warsaw, POLAND) B. Falkner (Philadelphia, PA, USA)
15.15-15.30 When and how to look for cerebrovascular FMD? 15.12-15.24 Daily life factors on primordial prevention
A. Persu (Brussels, BELGIUM) E. Lurbe (Valencia, SPAIN)
15.30-15.45 Acute coronary syndrome: when to look for FMD? 15.24-15.36 Ambulatory BP monitoring should be included in
D. Adlam (Leicester, UNITED KINGDOM) pediatric hypertension criteria
E. Wühl (Heidelberg, GERMANY)
15.36-15.48 Kidney damage in childhood primary hypertension
J. Flynn (Seattle, WA, USA)
42
15.00-16.00 - ROOM 5
15.18 ASSOCIATION OF HYPERTENSION WITH ALL-CAUSE
Oral Session 6B MORTALITY AMONG HOSPITALIZED PATIENTS WITH COVID-19
E. Rodilla 1, A. Saura 1, I. Jiménez 1, A. Mendizábal 1, A. Pineda-Cantedo 2,
E. Lorenzo-Hernández 2, M. Del Pilar Fidalgo-Montero 3,
COVID-19 AND HYPERTENSION
J.F. López-Cuervo 4, R. Gil-Sánchez 1, E. Rabadán-Pejenaute 5,
Chairpersons: C. Delles (Glasgow, UNITED KINGDOM), L. Abella-Vázquez 6, V. Giner-Galvañ 7, M. Nataya Solís-Marquínez 8,
T. Weber (Wels, AUSTRIA) R. Boixeda 9, A. De La Peña-Fernández 9, F. Javier Carrasco-Sánchez 9,
J.González-Moraleja 9, J. David Torres-Peña 9, M.E. Guisado-Espartero 9,
J. Escobar-Sevilla 9, M. Guzmán-García 9, M.D. Martín-Escalante 9,
15.00 INCREASED CARDIOVASCULAR DEATH RATES IN A Á.L. Martínez-González 9, J.M. Casas-Rojo 9, R. Gómez-Huelgas 2
COVID-19 LOW PREVALENCE AREA 1
Valencia, 2 Málaga, 3 Coslada, 4 Torrevieja, 5 Logroño,
R. Del Pinto, G. Desideri, L. Mammarella, S. Abballe, S. Dell’Anna, 6
Santa Cruz de Tenerife,7 San Juan de Alicante, 8 Avilés, 9 Own City,
S. Cicogna, D. Grassi, S. Sacco, C. Ferri SPAIN
L’Aquila, ITALY
15.24 ROLE OF ACE2 GLYCOSYLATION AND RHO KINASE
15.06 EVIDENCE OF A BLOOD PRESSURE REDUCTION INHIBITION IN THE INFECTIOUS/THERAPEUTIC PROCESS OF
DURING THE COVID-19 ASSOCIATED LOCKDOWN: A PLAUSIBLE COVID-19. INSIGHTS FROM GITELMAN’S AND BARTTER’S
EXPLANATION FOR THE OBSERVED DECLINES IN ACUTE SYNDROMES PATIENTS
CARDIOVASCULAR DISEASES? G. Bertoldi, L. Gianesello, M. Rigato, L. Sgarabotto, L. Calò
N. Girerd 1, C. Meune 2, K. Duarte 1, V. Vercamer 3, M. Lopez-Sublet 2, Padua, ITALY
J.-J. Mourad 4
1
Nancy, 2 Bobigny, 3 Issy les Moulineaux, 4 Paris, FRANCE 15.30 RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND COVID-19:
A SYSTEMATIC REVIEW AND META-ANALYSIS. EVIDENCE FOR
15.12 HYPERTENSION AND RENIN-ANGIOTENSIN SYSTEM SIGNIFICANT GEOGRAPHICAL DISPARITIES
BLOCKERS ARE NOT ASSOCIATED WITH EXPRESSION OF D. Patoulias, A. Katsimardou, K. Stavropoulos, K. Imprialos,
ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) IN THE KIDNEY M. Styliani Kalogirou, M. Doumas
X. Jiang 1, J. Eales 1, D. Scannali 1, A. Nazgiewicz 1, P. Prestes 2, M. Maier 2, Thessaloniki, GREECE
M. Denniff 3, X. Xu 1, S. Saluja 1, W. Wystrychowski 4, J. Zywiec 6,
E. Zukowska-Szczechowska 4, L.M. Burrell 7, A. Greenstein 1, 15.36 HYPERTENSION AND COVID-19: THE POSSIBLE ROLE OF
P. Bogdanski 5, B. Keavney 1, A.P. Morris 1, A. Heagerty 1, N.J. Samani 3, METALLOPROTEINASE-9 IN COVID-19 PATHOPHYSIOLOGY
T.J. Guzik 8, F.J. Charchar 2,3, M. Tomaszewski 1 C. Dávila Mesquita, A.E. Souza do Couto, L. Borges Campos,
1
Manchester, UNITED KINGDOM, 2 Ballarat, AUSTRALIA, 3 Leicester, B.C. Petroski Mora, F. Mestriner, T. Fernandes Vasconcelo,
UNITED KINGDOM, 4 Katowice, 5 Poznan, 6 Zabrze, POLAND, J. Michelon Barbosa, C. Curylofo Corsi, D. Ferro, M. Serra Ribeiro,
7
Melbourne, AUSTRALIA, 8 Glasgow, UNITED KINGDOM M. Gonçalves Menegueti, M. Auxiliadora Martins, C. Becari
Ribeirao Preto, BRAZIL
43
15.00-16.00 - ROOM 6
15.42 IN-HOSPITAL DIURETIC USE IS ASSOCIATED WITH WORSE
OUTCOME IN PATIENTS WITH COVID-19 ISH New Investigator Committee
M. Pengo, G. Stefanini, C. Pivato, D. Soranna, G. Zambra, A. Zambon,
C. Torlasco, G. Bilo, G. Condorelli, G. Parati Award Session
Milan, ITALY Chairpersons: C. Landry (Ottawa, CANADA),
R. Muralitharan (Clayton, AUSTRALIA)
15.48 IMPACT OF COVID-19 LOCKDOWN ON VASCULAR
STIFFNESS TRAJECTORIES IN FRANCE AND GERMANY 15.00 DIFFERENTIAL PREVALENCE AND ASSOCIATIONS OF
R.M. Bruno 1, J.-L. Pepin 2, J.-P. Empana 1, R.-Y. Yang 3, V. Vercamer 3, CHRONIC KIDNEY DISEASE BY FIVE ESTIMATORS IN A SOUTH
P. Jouhaud 3, P. Escorrou 3, P. Boutouyrie 1 AFRICAN POPULATION-BASED STUDY
1
Paris, 2 Grenoble, 3 Issy les Moulineaux, FRANCE N. Peer 1,2, J. George 3, C. Lombard 2, K. Steyn 2, N. Levitt 2,
A.-P. Kengne 1,2
1
Durban, 2 Cape Town, 3 Johannesburg, SOUTH AFRICA
15.07 PROSPECTIVE OBSERVATIONAL STUDY ASSESSING

AMBULATORY BLOOD PRESSURE IN PRIMARY ALDOSTERONISM
AFTER SURGICAL AND MEDICAL TREATMENT
T. Puar, M. Zhang, J. Khoo, S. Chew Chai
Singapore, SINGAPORE
15.14 PREVALENCE OF TYPE 2 DIABETES MELLITUS AMONG

KNOWN HYPERTENSIVES AT THE REGIONAL HOSPITAL BAMENDA,
CAMEROON
E. Ngeh, F. Ako Atabon
Bamenda, CAMEROON
15.21 INFLAMMATION AND SALT IN YOUNG ADULTS: THE

AFRICAN-PREDICT STUDY
S. Crouch 1, S. Botha-Le Roux 1, C. Delles 2, L.A. Graham 2, A.E. Schutte 1
1
Potchefstroom, SOUTH AFRICA, 2 Glasgow, UNITED KINGDOM
15.28 COMBINATION THERAPY IN PATIENTS WITH TYPE 2

DIABETES MELLITUS AND HEART FAILURE WITH REDUCED
EJECTION FRACTION
M.-A. Gaman, E. Codruta Dobrica, M.A. Cozma, C.C. Diaconu
Bucharest, ROMANIA
44
16.00-17.00 - AUDITORIUM
15.35 ANGIOTENSIN II-INDUCED ER STRESS RESPONSE Omron Academy Online
CONTRIBUTES TO PROFIBROTIC VSMC PHENOTYPE AND
SUBSEQUENT HYPERTENSIVE ARTERIAL STIFFNESS
INNOVATION IN THE ONLINE EDUCATION ON
S. Cicalese, H. Cooper, K. Preston, T. Kawai, R. Scalia, S. Eguchi
Philadelphia, PA, USA CARDIOVASCULAR DISORDERS IN
COLLABORATION WITH THE ESH
15.42 BLOOD PRESSURE PREVALENCE WITH STRATIFICATION Chairperson: G. Parati (Milan, ITALY)
AND ASSOCIATIONS: A COMMUNITY-BASED STUDY FROM
LONGITUDINAL COHORT HOUSEHOLD SURVEY 2019
N. Chakaraborty 1, K. Chakraborty 2, R. Nath Mitra 1, A. Saha 1, 16.00-16.25 Free, easy to use and up-to-date online education
P. Chatterjee 1, S. Manna 1, D. Mitra 1 platform developed by ESH in collaboration with
1
Kolkata, INDIA, 2 Baltimore, MD, USA OMRON
15.49 ASSOCIATION OF CHILDHOOD PHYSICAL EXAMINATION
AND LABORATORY PARAMETERS WITH HIGH BLOOD PRESSURE 16.25-16.50 Introducing OMRON Academy online for credible
IN JAPANESE YOUNG ADULTS cardiovascular education courses
T. Azegami 1, K. Uchida 1, F. Arima 1, Y. Sato 2, M. Awazu 3, M. Inokuchi 1, R. Asmar (Paris, FRANCE)
A. Takeda 1, H. Itoh 2, M. Tokumura 1, M. Mori 1
1
Yokohama-Shi, 2 Tokyo, JAPAN 16.50-17.00 Discussion
45
16.00-16.45 - ROOM 1 16.00-17.00 - ROOM 2
Minisymposium Oral Session 7A

supported by Menarini Group
TREATMENT ADHERENCE
NO(T) A CLASS EFFECT Chairpersons: M. Burnier (Lausanne, SWITZERLAND)
Chairpersons: A.J. Manolis (Athens, GREECE), M. Tomaszewski (Manchester, UNITED KINGDOM)
16.00 LECTURE
16.00-16.05 Introduction WHITE COAT AND MASKED HYPERTENSION. OLD AND NEW
A.J. Manolis (Athens, GREECE), PROBLEMS
B. Williams (London, UNITED KINGDOM) G. Mancia (Milan, ITALY)
16.05-16.15 A crowded class 16.15 PHYSICIAN- AND PATIENT REPORTED ADHERENCE

B. Williams (London, UNITED KINGDOM) TO ANTIHYPERTENSIVE DRUGS VERIFIED BY SERUM DRUG
CONCENTRATION
16.15-16.25 NO: a unique feature O. Undrum Bergland, C. Lund Søraas, L. Vernås Halvorsen, S. Rognstad,
R. Kreutz (Berlin, GERMANY) U. Hjørnholm, V. Kjær, M. Stokke Opdal, M. Rostrup, A.C. Larstorp,
A. Høieggen, F. Elmula, M. Fadl Elmula
16.25-16.35 The optimal therapeutic option for your hypertensive Oslo, NORWAY
patient
A.J. Manolis (Athens, GREECE) 16.22 LONG-TERM ADHERENCE TO ANTIHYPERTENSIVE
TREATMENT BY URINARY/PLASMA DETECTION IN PATIENTS WITH
16.35-16.45 Q&A and closing remarks RESISTANT HYPERTENSION IN THE RENAL DENERVATION FOR
HYPERTENSION (DENER-HTN) TRIAL
B. Kably 1, D. Fouassier 1, A. Lorthioir 1, P. Gosse 2, P. Delsart 3,
P.-Y. Courand 4, T. Denolle 5, H. Pereira 1, E. Billaud 1, M. Azizi 1
1
Paris, 2 Bordeaux, 3 Lille, 4 Lyon, 5 Dinard, FRANCE
16.29 THE PREVALENCE OF DRUG-RELATED ADVERSE

REACTIONS AMONG HYPERTENSIVE PATIENTS
K. Stolarz-Skrzypek, M. Bijak, A. Olszanecka, W. Wojciechowska,
D. Czarnecka
Krakow, POLAND
46
16.00-17.00 - ROOM 3
16.36 TWO-DRUG FIXED-DOSE COMBINATION AS INITIAL
ANTIHYPERTENSIVE TREATMENT STRATEGY CONFERS HIGHER Oral Session 7B
MEDICATION ADHERENCE COMPARED TO MONOTHERAPY
F. Rea 1, L. Savaré 1, G. Corrao 1, G. Mancia 1,2
BIOMARKERS
1
Milan, 2 Monza, ITALY
Chairpersons: H.-P. Marti (Bergen, NORWAY),
16.43 LECTURE A. Januszewicz (Warsaw, POLAND)
THE SPRINT MARATHON: THE RACE GOES ON
S. Oparil (Birmingham, AL, USA) 16.00 ASSOCIATIONS OF RENALASE WITH BLOOD PRESSURE
AND THE RISK OF HYPERTENSION IN CHINESE ADULTS
Y. Wang, K. Gao, C. Chen, Y. Yan, Y. Yuan, K.-K. Wang, J.-W. Hu,
C. Chu, Q. Ma, B.-W. Fu, Y.-Y. Liao, M. Li, Y. Sun, M.-J. He, J.-J. Mu
Xi’an, CHINA
16.07 GROWTH DIFFERENTIATION FACTOR-15 IS AN

INDEPENDENT PREDICTOR OF CARDIOVASCULAR DISEASE IN
JAPANESE PATIENTS WITH CARDIOVASCULAR RISK FACTORS:
THE J-HOP STUDY
K. Negishi, S. Hoshide, Y. Ishiyama, H. Shimizu, M. Shinpo, K. Kario
Tochigi, JAPAN
16.14 EARLY HYPERTENSION: EXPLORING THE VASCULAR

PHENOTYPE
E. Murray, T. Guzik, C. Delles
Glasgow, UNITED KINGDOM
16.21 RELATIOSHIP BETWEEN DIURETIC RELATED

HYPERURICEMIA AND CARDIOVASCULAR EVENTS: DATA FROM
THE URRAH (URIC ACID RIGHT FOR HEART HEALTH) STUDY
A. Maloberti 1, M. Bombelli 1, R. Facchetti 1, A. Virdis 2, E. Casiglia 3,
V. Tikhonoff 3, C.M. Barbagallo 4, M. Cirillo 5, G. Desideri 6, C. Ferri 6,
F. Galletti 7, G. Iaccarino 5, F. Mallamaci 8, S. Masi 2, A. Mazza 1,
M.L. Muiesan 10, M. Salvetti 10, P. Palatini 1, R. Pontremoli 1, P. Verdecchia 1,
M. Volpe 1, G. Grassi 1, C. Giannattasio 1, C. Borghi 9
1
Milan, 2 Pisa, 3 Padua, 4 Palerno, 5 Salerno, 6 L’Aquila, 7 Naples,
8
Reggio Calabria, 9 Bologna, 10 Brescia, ITALY
47
16.00-17.00 - ROOM 4
16.28 PLASMA FATTY ACIDS AND THE RISK OF VASCULAR AND
MORTALITY OUTCOMES IN INDIVIDUALS WITH TYPE 2 DIABETES: Joint Session ESH-ISH-BIHS - Young
RESULTS FROM THE ADVANCE STUDY
K. Harris 1, M. Oshima 1,2, N. Sattar 3, P. Wurtz 4, M. Jun 1, P. Welsh 3, investigator Symposium
J. Chalmers 1, M. Woodward 1,5
1
Sydney, AUSTRALIA, 2 Ishikawa, JAPAN, 3 Glasgow, UNITED KINGDOM, DEVELOPING COLLABORATIONS TO FURTHER YOUR
4
Helsinki, FINLAND, 5 Oxford, UNITED KINGDOM CAREER
16.35 IDENTIFICATION OF CANDIDATE BIOMARKERS FOR Chairpersons: P. Christofidou (London, UNITED KINGDOM)
SALT SENSITIVITY OF BLOOD PRESSURE BY INTEGRATED A. Montezano (Glasgow, UNITED KINGDOM)
BIOINFORMATICS ANALYSIS
C. Chen, G. Liu, C. Chu, W. Zheng, J. Hu, Y. Wang, Q. Ma, Y. Yan,
Y. Yuan, Y. Liao, J. Mu 16.00-16.10 Why be a member of ESH/ISH/BIHS as young
Xi’an, CHINA investigators?
L. Faconti (London, UNITED KINGDOM),
16.42 REFERENCE RANGES AND CUT-OFF VALUES FOR B. Wynne (Salt Lake City, GA, GEORGIA)
SIMULTANEOUS MONITORING OF RAS BLOCKER EFFICACY AND
SCREENING FOR SECONDARY HYPERTENSION USING RAAS 16.10-16.20 Interacting with senior delegates at a conference: Do’s
TRIPLE-A PROFILING and don’ts
M. Poglitsch 1, L. Foco 2, M. Gögele 2, P.P. Pramstaller 2, C. Pattaro 2 J.K. Cruickshank (London, UNITED KINGDOM)
1
Vienna, AUSTRIA, 2 Bolzano, ITALY
16.20-16.30 Using my conference presentation to meet
16.49 F-18 FDG PET/CT CAN BE USED AS AN IMAGING collaborators abroad
BIOMARKER FOR REFLECTING SYNTHETIC VASCULAR SMOOTH F. Saladini (Padua, ITALY)
MUSCLE CELL ACTIVITY IN THE ANIMAL MODEL OF VASCULAR
REMODELING DISORDER 16.30-16.40 Making the most of the opportunities from the Society
K. Pahk, C. Joung, S. Kim, W.-K. Kim to forge new connections
Seoul, SOUTH KOREA F. Marques (Melbourne, AUSTRALIA)
16.40-16.50 Aspirational talk - Developing large collaborative

research projects through your society
16.50-17.00 Questions from the audience
48
16.00-17.00 - ROOM 5
16.43 CORRELATION OF ANKLE-BRACHIAL INDEX WITH
Oral Session 7C SEVERITY OF CORONARY ARTERY DISEASE IN PATIENTS
HOSPITALIZED FOR ACUTE MYOCARDIAL INFARCTION
A. Koumelli, K. Tsioufis, K. Konstantinou, E. Mantzouranis, A. Kasiakogias,
MULTIMORBIDITY AND CO-MORBIDITIES
K. Dimitriadis, A. Milkas, D. Konstantinidis, I. Leontsinis, D. Tousoulis
Chairpersons: C. Borghi (Bologna, ITALY), Athens, GREECE
P. van de Borne (Brussels, BELGIUM)
16.50 RELATIONSHIPS BETWEEN ANTI-HYPERTENSIVE DRUGS
AND NOCTURIA: A SYSTEMATIC REVIEW
16.00 ISOLATED SYSTOLIC HYPERTENSION VERSUS COMBINED Y. Akasaki, T. Kubozono, K. Higuchi, M. Ohishi
SYSTOLIC-DIASTOLIC HYPERTENSION AS PREDICTOR OF ATRIAL Kagoshima, JAPAN
FIBRILATION: DATA FROM AN 8-YEAR-FOLLOW-UP STUDY
D. Konstantinidis, K. Tsioufis, I. Liatakis, E. Koutra, I. Leontsinis,
M. Kouremeti, P. Iliakis, N. Karaminas, F. Tatakis, P. Papakonstantinou,
A. Anastasiou, D. Mourtzoukou, E. Siafi, N. Kakouri, M. Dimitriadi,
D. Tousoulis
Athens, GREECE
16.07 OBSTRUCTIVE SLEEP APNEA IS AN INDEPENDENT

PREDICTOR OF ARTERIAL STIFFNESS IN HYPERTENSIVE PATIENTS
H. Rietz 1, H. Hellqvist 1, T. Kahan 1, D. Sommermeyer 3, J. Hedner 2,
L. Grote 2, J. Spaak 1
1
Stockholm, 2 Gothenburg, SWEDEN, 3 Mannheim, GERMANY
16.14 ASSESSMENT OF URODYNAMICS AND CONCENTRATION

FUNCTION OF PARENCHYMA IN PATIENTS WITH ARTERIAL
HYPERTENSION AND GOUT
M. Gromova, O. Kislyak, V. Tsurko, A. Kashkadayeva, S. Averinova,
A. Aliokhin
Moscow, RUSSIA
16.36 ARTERIAL STIFFNESS AND WAVE REFLECTIONS IN

PATIENTS WITH SERONEGATIVE SPONDYLOARTHROPATHIES
TREATED WITH TUMOR NECROSIS ALPHA BLOCKERS
F. Bozzao, N. Colapietro, C. Xodo, A. Grillo, M. Rovina, O. Magazzino,
K. Giraldi Smitova, R. Carretta, S. Bernardi, P. Tomietto, F. Fischetti,
B. Fabris
Trieste, ITALY
49
16.00-17.00 - ROOM 6
Workshop
IMMUNITY AND INFLAMMATION IN HYPERTENSION -
FROM BASIC MECHANISMS TO CLINICAL
TRANSLATION
Chairpersons: T. Guzik (Glasgow, UNITED KINGDOM),
E. Schiffrin (Montreal, CANADA)
16.00-16.20 Neuroimmune interfaces in hypertension

G. Lembo (Rome, ITALY)
16.20-16.40 Innate immunity mechanisms in hypertension

G. Drummond (Melbourne, AUSTRALIA)
E. Schiffrin (Montreal, CANADA),
T. Guzik (Glasgow, UNITED KINGDOM),
G. Lembo (Rome, ITALY),
G. Drummond (Melbourne, AUSTRALIA),
D. Carnevale (Rome, ITALY)
50
TUESDAY, APRIL 13 SCIENTIFIC PROGRAMME
11.00-12.00 - AUDITORIUM 11.00-12.00 - ROOM 1
Topical Workshop on Hot Issues Joint Session ESH-ISH-CHL

TREATMENT ADHERENCE AND INERTIA IN OUT-OF-OFFICE BLOOD PRESSURE MEASUREMENT
HYPERTENSION Chairpersons: G.S. Stergiou (Athens, GREECE),
Chairpersons: F.P. Cappuccio (Coventry, UNITED KINGDOM), J. Wang (Shanghai, CHINA)
G. Mancia (Milan, ITALY)
11.00-11.05 Opening
11.00-11.12 Measuring adherance in research and clinical practice: G.S. Stergiou (Athens, GREECE)
any improvement?
M. Burnier (Lausanne, SWITZERLAND) 11.05-11.20 Blood pressure measurement in public places
Y. Li (Shangai, CHINA)
11.12-11.24 Therapeutic inertia: causes and impact against
achievement of optimal treatment 11.20-11.35 Masked hypertension in treated hypertension: the
F.P. Cappuccio (Coventry, UNITED KINGDOM) MASTERS Trial
11.24-11.36 Adherence, inertia and cardiovascular risk: news from
the Lombardy database 11.35-11.50 Cigarettes smoking and masked hypertension
G. Mancia (Milan, ITALY) D.-Y. Zhang (Shanghai, CHINA)
11.36-11.48 What have we learned about managing non-adherence 11.50-12.00 Discussion and Closing
to antihypertensive treatment from LC-MS/MS-based J. Wang (Shanghai, CHINA)
analyses of blood/urine
M. Tomaszewski (Manchester, UNITED KINGDOM)
53
11.00-12.00 - ROOM 2 11.00-12.00 - ROOM 3
Joint Session ESH-ISH - Indian Society of Workshop

Hypertension
24 HOUR BP PROFILE AND SYMPATHETIC DRIVE
FEATURES OF HYPERTENSION AND Chairpersons: M. Esler (Melbourne, AUSTRALIA),
CARDIOVASCULAR DISEASE IN INDIA G. Grassi (Milan, ITALY)
Chairpersons: R. Kreutz (Berlin, GERMANY),

S. Narasingan (Chennai, INDIA) 11.00-11.20 SNS, blood pressure variability and 24hrs blood
pressure
K. Narkiewicz (Gdansk, POLAND)
11.00-11.10 Increasing disease burden imposed by hypertension in
India 11.20-11.40 SNS, masked hypertension, white coat hypertension,
J. Dalal (Mumbai, INDIA) controlled and uncontrolled
K. Kario (Tochigi, JAPAN)
11.10-11.20 Clinical hypertension course developed by Public
Health Foundation of India: a commanding educational 11.40-12.00 Discussion
tool of enduring value
11.20-11.30 Unique features of cardiovascular disease in South Asia

R. Agarwala (Meerut, INDIA)
11.30-11.40 Patterns of pharmacotherapy of hypertension in India

G.S. Wander (Ludhiana, INDIA)
11.40-11.45 East meets West finally: concluding summary

V.S. Ram (Hyderabad, INDIA)
54
11.00-12.00 - ROOM 4 11.00-12.00 - ROOM 5
Workshop Workshop
GLOBAL TRAINING PROGRAMS TO IMPROVE European Council for Cardiovascular Research (ECCR) –
HYPERTENSION CARE: FUNDAMENTAL BUT High blood pressure research council of Australia (HBPRCA)
UNDERAPPRECIATED ASPECT SOME NEW CONCEPTS IN HYPERTENSION
Chairpersons: A. Schutte (Sydney, AUSTRALIA), Chairpersons: M. Schlaich (Perth, AUSTRALIA),
X.-H. Zhang (Urumqi, CHINA) T. Unger (Maastricht, THE NETHERLANDS)
11.00-11.15 Experience of Virtual Academy in central and south 11.00-11.12 Update on estrogens in cardiovascular disease
America M. Barton (Zurich, SWITZERLAND)
P. Ordunez (Washington DC, USA)
11.12-11.24 Sympatho-inhibitory effects of dexmedetomidine
11.15-11.30 Experience of in-person training in China reduces catecholamine requirements to restore target
X.-H. Zhang (Urumqi, CHINA) blood pressure and preserves renal oxygenation and
function in septic acute kidney injury
11.30-11.45 Short videos and a free online course for non- Y.R. Lankadeva (Parkville, AUSTRALIA)
physicians
K. Matsushita (Baltimore, MD, USA) 11.24-11.36 Inhibition of ACE C-domain and neprilysin in a chronic
angiotensin II-dependent mouse model of hypertension
11.45-12.00 Discussion R. Alves-Lopes (Glasgow, UNITED KINGDOM)
11.36-11.48 Embedding better blood pressure measurement in

existing primary care services
N. Chapman (Hobart, AUSTRALIA)
55
11.00-12.00 - ROOM 6
11.35 IMMUNE CELLS MEDIATED EFFECTS OF SODIUM
Oral Session 8A CHLORIDE ON THE DEVELOPMENT OF VASCULAR INFLAMMATION
AND ABDOMINAL AORTIC ANEURYSM IN ANGIOTENSIN
II-TREATED APOE-KO MICE
INFLAMMATION AND IMMUNITY
J. Stegbauer, M. Yakoub, M. Rahman, L. Hering, S. Potthoff, D. Argov,
Chairpersons: T. Guzik (Glasgow, UNITED KINGDOM), U. Flögel, L. Christian Rump, S. Temme
G.P. Rossi (Padua, ITALY) Düsseldorf, GERMANY
11.42 UNCOVERING ASSOCIATIONS BETWEEN BLOOD

11.00 CHOLECALCIFEROL SUPPLEMENTATION AMELIORATES PRESSURE PHENOTYPES AND IMMUNE TRAITS IN TWINSUK
IMMUNE DYSFUNCTION IN OBESE HYPERTENSIVE PATIENTS P. Christofidou 1, C. Menni 1, T. Liechti 2, M. Roederer 2, T. Spector 1,
C. Santos, A. Monteiro, A. Esgalhado, M. Fonseca, M. Castelo-Branco M. Mangino 1
Covilhã, PORTUGAL 1
London, UNITED KINGDOM, 2 Bethesda, MD, USA
11.07 ROLE OF ATYPICAL CHEMOKINE RECEPTOR 2
IN PERIVASCULAR ADIPOSE TISSUE INFLAMMATION IN 11.49 ANGIOTENSIN II INCREASES FORMATION OF NEUTROPHIL
ANGIOTENSIN II DEPENDENT HYPERTENSION EXTRACELLULAR TRAPS: ROLE IN HYPERTENSION AND DIABETES
T. Mikolajczyk 1, D. Skiba 1, F. Vidler 2, S. Love 2, A. Justo-Junior 2, C. Landry, J.-F. Thibodeau, A. Gutsol, C.R.J. Kennedy, D. Burger
R. Nosalski 2, D. Graham 2, P. Maffia 2, G. Graham 2, T. Guzik 2 Ottawa, CANADA
1
Krakow, POLAND, 2 Glasgow, UNITED KINGDOM
11.14 RNA-SEQ REVEALS HSP90 AS A REGULATOR FOR

INTERLEUKIN 6-MEDIATED ACTIVATION OF NCC VIA THE
MINERALOCORTICOID RECEPTOR
A. Moseley 1, M. Zhang 1, M. Tansey 2, B. Ko 3, D. Eaton 1, B. Wynne 1,4
1
Atlanta, GA, 2 Gainesville, FL, 3 Chicago, IL, 4 Salt Lake City, UT, USA
11.21 TRPM7 IS PROTECTIVE AGAINST CARDIOVASCULAR

DAMAGE INDUCED BY ALDOSTERONE AND SALT
F.J. Rios 1, Z.-G. Zou 1, A.P. Harvey 1, K.Y. Harvey 1, K.B. Neves 1,
R. Alves-Lopes 1, S.E.F. Nichol 1, L.L. Camargo 1, V. Chubanov 2,
T. Gudermann 2, A.C. Montezano 1, R.M. Touyz 1
1
Glasgow, UNITED KINGDOM, 2 Munich, GERMANY
11.28 RENALASE PROTECTS AGAINST SALT-INDUCED KIDNEY

INJURY AND INFLAMMATION BY INHIBITING THE ACTIVATION OF
THE AKT-1 SIGNALING PATHWAYS
K. Wang, Y. Wang, Y. Yuan, Q. Ma, Y. Yan, Y. Liao, J. Mu
Xi’an, CHINA
56
Plenary Session Satellite Symposium

Chairpersons: A. Schutte (Sydney, AUSTRALIA), supported by Merck
M. Tomaszewski (Manchester, UNITED KINGDOM)
DO WE NEED BETA BLOCKERS IN HYPERTENSION?
Chairperson: G. Mancia (Milan, ITALY)
PRESIDENTIAL LECTURE
12.00-12.30 Why a collective global effort is needed to improve
blood pressure control in low resource settings 13.00-13.05 Introduction
A. Schutte (Sydney, AUSTRALIA) G. Mancia (Milan, ITALY)

12.20-12.40 Presentation of ISH Awards 13.05-13.30 Sympathetic overdrive in hypertension: a rationale for
ISH Robert Tigerstedt Lifetime Achievement Award beta blocker recommendation in the guidelines?
ISH Developing World Award
ISH Paul Korner Award supported by the High Blood 13.30-13.55 Single pill combinations in hypertension: an opportunity
Pressure Research Foundation for multiple modes of action
S.E. Kjeldsen (Oslo, NORWAY)
ISH Award of Excellence for Research in Cardiovascular
Health and Disease in Women 13.55-14.00 Discussion
ISH Honour for Senior Women Researchers
ISH Mid-Career Award for Women Researchers
ISH Distinguished Fellow Awards
ISH Austin Doyle Award
ISH New Investigator Oral Presentation Awards
ISH Fellows
ISH Franz Volhard Award and Lectureship for
Outstanding Research
12.40-13.00 ISH Franz Volhard Awardee Lecture

E. Schiffrin (Montreal, CANADA)
57
13.00-14.00 - ROOM 1 13.00-14.00 - ROOM 2
Teaching Seminar Oral Session 9A

SESSION 2 THERAPEUTICS AND CLINICAL TRIALS
Chairpersons: J.P. Chalmers (Sydney, AUSTRALIA), Chairpersons: M. Azizi (Paris, FRANCE),
P. van de Borne (Brussels, BELGIUM) S. Padmanabhan (Glasgow, UNITED KINGDOM)
13.00-13.12 Is treatment of heart failure different in hypertensive 13.00 LECTURE

patients? SGLT2 INHIBITORS TO PREVENT AND TREAT HEART FAILURE
A.M. Heagerty (Manchester, UNITED KINGDOM) J. McMurray (Glasgow, UNITED KINGDOM)
13.12-13.24 CV effects of new antidiabetic drugs: good or bad? 13.15 EFFECTS OF FEBUXOSTAT ON CAROTID INTIMA-MEDIA
H.A.J. Struijker-Boudier (Maastricht, THE NETHERLANDS) THICKNESS IN ASYMPTOMATIC HYPERURICEMIA: A RANDOMIZED
CLINICAL TRIAL (PRIZE)
A. Tanaka 1, I. Taguchi 2, H. Teragawa 3, N. Ishizaka 4, T. Murohara 5,
13.24-13.36 Pheochromocytoma: how to detect, how to manage?
K. Node 1
A. Prejbisz (Warsaw, POLAND) 1
Saga, 2 Koshigaya, 3 Hiroshima, 4 Takatsuki, 5 Nagoya, JAPAN
13.36-13.48 Diuretic induced hyponatremia - pathogenesis and 13.22 OPTIMAL DRUGS FOR MEDICATION REDUCTION:
management SECONDARY ANALYSIS OF THE OPTIMISE MEDICATION
M. Glover (Nottingham, UNITED KINGDOM) REDUCTION TRIAL
J. Sheppard 1, M. Lown 2, J. Burt 3, E. Temple 1, G. Ford 1, R. Hobbs 1,
13.48-14.00 Discussion P. Little 2, J. Mant 3, R. Payne 4, R. McManus 1
1
Oxford, 2 Southampton, 3 Cambridge, 4 Bristol, UNITED KINGDOM
13.29 CLINICAL IMPLICATION OF ASSESSING QUANTITATIVE

PLASMA CONCENTRATIONS OF ANTIHYPERTENSIVE DRUGS
L. Peeters-Kalicharan, L. Feyz, J. Daemen, T. van Gelder, B. Koch,
J. Versmissen
Rotterdam, THE NETHERLANDS
13.36 ANTIHYPERTENSIVE EFFECTS AND SAFETY OF

ESAXERENONE IN HYPERTENSIVE PATIENTS WITH MODERATE
KIDNEY DYSFUNCTION
S. Ito 1, H. Itoh 2, H. Rakugi 3, Y. Okuda 2, S. Iijima 2
1
Shiroishi, 2 Tokyo, 3 Osaka, JAPAN
58
13.00-14.00 - ROOM 3
13.43 STRATIFIED EFFECTS OF BLOOD PRESSURE-LOWERING
TREATMENT ON LONG-TERM BLOOD PRESSURE: A META- Oral Session 9B
ANALYSIS OF INDIVIDUAL-LEVEL DATA OF 334,219 PARTICIPANTS
FROM 50 RANDOMIZED TRIALS
LARGE ARTERIES
D. Canoy 1, E. Copland 1, R. Ramakrishnan 1, A.-C. Pinho-Gomes 1,
M. Nazarzadeh 1, Z. Bidel 1, G. Salimi-Khorshidi 1, M. Woodward 1,2, Chairpersons: C. McEniery (Cambridge, UNITED KINGDOM),
B.R. Davis 3, C.J. Pepine 4, J. Chalmers 2, K. Teo 5, K. Rahimi 1 B. Spronck (New Haven, CT, USA)
1
Oxford, UNITED KINGDOM, 2 Sydney, AUSTRALIA, 3 Houston, TX,
4
Gainesville, FL, USA, 5 Hamilton, Toronto, CANADA
13.00 GENETIC BACKGROUND DOMINATES FIBROTIC AORTIC
13.50 OPTIMAL THRESHOLDS FOR AMBULATORY BLOOD REMODELING DURING ANGIOTENSIN-INDUCED HYPERTENSION
PRESSURE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN MICE
H. Jaehyung, L. Chanjoo, K. Hyoeun, C. Kyeong-Hyeon, O. Jaewon, B. Spronck 1,2, A.W. Caulk 1, A.B. Ramachandra 1, S.-I. Murtada 1,
L. Sang-Hak, K. Seok-Min, P. Sungha A. Rojas 1, C.-S. He 1, M.R. Bersi 3, G. Tellides 1, J.D. Humphrey 1
Seoul, SOUTH KOREA 1
New Haven, CT, USA, 2 Maastricht, THE NETHERLANDS,
3
Nashville, TN, USA
13.07 AGE-SPECIFIC ACUTE CHANGES IN CAROTID-FEMORAL

PULSE WAVE VELOCITY DURING HEAD-UP TILTING
G. Pucci 1, A. Avolio 3, B. Spronk 4, L. Tap 2, G. Vaudo 1, F. Anastasio 5,
A. Van de Meiracker 2, F. Mattace-Raso 2
1
Perugia, ITALY, 2 Rotterdam, THE NETHERLANDS, 3 Sidney, AUSTRALIA,
4
New Haven, CT, USA, 5 Sondrio, ITALY
13.14 A HIGH ALDOSTERONE TO RENIN RATIO MEDIATES

MICROVASCULAR AND MACROVASCULAR DAMAGE IN NEWLY-
DIAGNOSED, TREATMENT-NAÏVE ESSENTIAL HYPERTENSION
A. Mahmud 1, T. Barhoumi 1, A.A. Aklabi 1, J. Feely(Late) 2, B. Silke 2
1
Riyadh, SAUDI ARABIA, 2 Dublin, IRELAND
13.21 ASSOCIATION OF CARDIOVASCULAR ENDPOINTS AND

MORTALITY WITH CENTRAL AND PERIPHERAL PULSATILE BLOOD
PRESSURE COMPONENTS
Q. Huang 1, L. Aparicio 2, L. Thijs 3, F.-F. Wei 3, J. Melgarejo 3, Y.-B. Cheng 1,
C.-S. Sheng 1, W.-Y. Yang 3, N. Gilis-Malinowska 4, J. Boggia 5, T. Niiranen 6,
W. Wojciechowska 7, K. Stolarz-Skrzype 7, J. Barochiner 2, V. Tikhonoff 8,
59
E. Casiglia 8, K. Narkiewicz 4, J. Filipovský 9, D. Czarnecka 7, 13.00-14.00 - ROOM 5

K. Kawecka-Jaszcz 7, A. Jula 6, T. Vanassche 3, P. Verhamme 3,
H. Struijker-Bouder 10, J.-G. Wang 1, Z.-Y. Zhang 3, Y. Li 1, J. Staessen 3 Oral Session 9C
1
Shanghai, CHINA, 2 Buenos Aires, ARGENTINA, 3 Leuven, BELGIUM,
4
Gdansk, POLAND, 5 Montevideo, URUGUAY, 6 Turku, FINLAND,
CHILDREN AND ADOLESCENTS
7
Kraków, POLAND, 8 Padua, ITALY, 9 Pilsen, CZECH REPUBLIC,
10
Maastricht, THE NETHERLANDS Chairpersons: R. Kruger (Potchefstroom, SOUTH AFRICA),
S. Stabouli (Thessaloniki, GREECE)
13.28 ARTERIAL STIFFNESS AND ORTHOSTATIC BLOOD
PRESSURE CHANGES IN HYPERTENSIVE ADULTS – RESULTS
FROM SEPHAR III SURVEY 13.00 EARLY DETERMINANTS OF CHILDHOOD BLOOD
O.F. Gheorghe Fronea 1, R. Darabont 1, C. Pop 2, M. Dorobantu 1 PRESSURE AT AGE 6: THE GECKO DRENTHE AND ABCD BIRTH
1
Bucharest, 2 Baia Mare, ROMANIA COHORTS
T. Xie 1, F. Falahi 1, T. Schmidt-Ott 1, T. Vrijkotte 2, E. Corpeleijn 1,
13.35 DIFFERENCE BETWEEN CHRONOLOGICAL AND VASCULAR H. Snieder 1
AGE AS A PREDICTOR FOR CARDIOVASCULAR EVENTS - 1
Groningen, 2 Amsterdam, THE NETHERLANDS
IDENTIFICATION OF PATIENTS WITH SUPERNORMAL VASCULAR
AGING (SUPERNOVA) 13.07 EVALUATION OF CENTRAL HEMODYNAMICS USING
R.M. Bruno 1, P. Nilsson 2, G. Engsrtöm 2, B. Wadström 2, J.-P. Empana 1, THE RADIAL ARTERIAL PULSE WAVE IN CHILDREN AND YOUNG
P. Boutouyrie 1, S. Laurent 1 ADULTS
1
Paris, FRANCE, 2 Malmö, SWEDEN T. Murakami, M. Shiraishi, A. Takeda
Sapporo, JAPAN
13.42 CAROTID-TO-FEMORAL PULSE TRANSIT TIME VARIABILITY
PREDICTS ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN 13.14 SYSTOLIC BLOOD PRESSURE AT BIRTH: THE IMPACT OF
CHINESE AND SWEDISH ELDERLY MOTHER´S OBESITY
D. An 1, I. Faqir Muhammad 2, Q.-H. Guo 1, Y. Borné 2, C.-S. Sheng 1, J. Alvarez 1,2, M. I. Torro 1,2, P. Redon 1,2, F. Aguilar 1,2, J. Redon 1,2,
M. Persson 2, Y.-B. Cheng 1, J.-G. Wang 1, G. Engström 2, Y. Li 1, E. Lurbe 1,2
P. Nilsson 2 1
Madrid, 2 Valencia, SPAIN
1
Shanghai, CHINA, 2 Malmö, SWEDEN
13.21 METHODS TO RECTIFY DISCREPANCIES WITH ADULT
13.49 RELATIONSHIP BETWEEN ARTERIAL STIFFNESS, BLOOD PRESSURE GUIDELINES
PHYSICAL ACTIVITY & SEDENTARY TIME IN A YOUNG MIDDLE- N. Larkins, T. Mori, C. Choong, M. Schlaich, L. Beilin
EASTERN POPULATION Perth, AUSTRALIA
A. Mahmud 1, T. Dalton 2, J. Nalin 2, M. Nalin 2, O. Merrigan 2, A. Saud 2,
R. Hamadah 2
1
Riyadh, SAUDI ARABIA, 2 Manama, BAHRAIN
60
13.28 IS BP LOAD ON AMBULATORY MONITORING A PREDICTOR
OF TARGET ORGAN DAMAGE IN YOUTH? THE SHIP AHOY STUDY May Measurement Month
G. Hamdani 1, M. Ferguson 2, M. Lande 3, K. Meyers 4, J. Samuels 5,
J.T. Flynn 6, E.M. Urbina 7 Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM),
1
Petah Tikva, ISRAEL, 2 Boston, MA, 3 Rochester, NY, 4 Philadelphia, PA, A. Schutte (Sydney, AUSTRALIA)
5
Houston, TX, 6 Seattle, WA, 7 Cincinnati, PH, USA
13.35 KEEP THE FIRST READING: AN ARGUMENT FOR THE 14.00-14.10 Rationale, methods, key results 2017 & 2018
IMPORTANCE OF THE FIRST OFFICE BLOOD PRESSURE READING N.R. Poulter (London, UNITED KINGDOM)
IN CHILDREN
R. Myette, J. Feber 14.10-14.25 MMM19 global results
Ottawa, CANADA T. Beaney (London, UNITED KINGDOM)
13.42 TRENDS IN OFFICE AND AMBULATORY BP ACROSS 14.25-14.35 Summary of MMM posters and abstracts
PEDIATRIC AGE G.S. Stergiou (Athens, GREECE)
E. Lurbe 1,2, J. Alvarez 1,2, M.I. Torro 1,2, J. Redon 1,2, F. Aguilar 1,2,
P. Redon 1,2 14.35-14.55 Regional and national presentations
1
Madrid, 2 Valencia, SPAIN China - J. Wang (Shanghai, CHINA)
India - M. Patil (Pune, INDIA)
13.49 HYPERTENSION PHENOTYPES IN YOUNG INDIVIDUALS Argentina - M. Salazar (La Plata, ARGENTINA)
DEFINED BY OFFICE, AMBULATORY AND HOME BLOOD Kenya - E. Ogola (Nairobi, KENYA)
PRESSURE MEASUREMENT: PREVALENCE AND ASSOCIATION
WITH TARGET ORGAN DAMAGE 14.55-14.58 MMM21
M.E. Zeniodi, A. Ntineri, A. Kollias, G. Servos, I. Moyssakis, A. Destounis, N.R. Poulter (London, UNITED KINGDOM)
A. Vazeou, G. S. Stergiou
Athens, GREECE 14.58-15.00 Closing remarks
A.F. Dominiczak (Glasgow, UNITED KINGDOM)
61
14.00-15.00 - ROOM 1
14.28 PREVALENCE OF PRIMARY ALDOSTERONISM AND
Oral Session 10A HYPOKALEMIA IN 5,100 PATIENTS REFERRED TO A TERTIARY
HYPERTENSION UNIT
J. Burrello 1, S. Monticone 1, I. Losano 1, G. Cavaglia’ 1, F. Buffolo 1,
ENDOCRINE HYPERTENSION
M. Tetti 1, M. Covella 1, F. Rabbia 1, F. Veglio 1, B. Pasini 1, T.A. Williams 1,2,
Chairpersons: D. Hering (Gdansk, POLAND) P. Mulatero 1
P. Mulatero (Turin, ITALY) 1
Turin, ITALY, 2 Munich, GERMANY
14.35 EXCESS ALDOSTERONE RELATIVE TO PLASMA RENIN

14.00 OBSTRUCTIVE SLEEP APNEA AND PRIMARY AND ANGIOTENSIN II ASSOCIATES POSITIVELY WITH CENTRAL
ALDOSTERONISM: A MULTICENTER CROSS-SECTIONAL STUDY SYSTOLIC BLOOD PRESSURE IN YOUNG BLACK AFRICANS
F. Buffolo 1, Q. Li 2, S. Monticone 1, D.A. Heinrich 3, A. Mattei 1, J. Pieroni 1, L. Gafane-Matemane, N. Mokae, Y. Breet, A.E. Schutte
M. Mei 2, S. Yang 2, Y.-H. Hu 4, M.-C. Yang 4, C. Sabbadin 6, F. Pizzolo 7, Potcheftstroom, SOUTH AFRICA
G. Giacchetti 5, F. Fallo 6, F. Veglio 1, M. Reincke 3, V.-C. Wu 4, P. Mulatero 1
1
Turin, ITALY, 2 Chongqing, CHINA, 3 München, GERMANY, 14.42 THE 2020 ITALIAN SOCIETY OF HYPERTENSION (SIIA)
4
Taipei, TAIWAN, 5 Ancona, 6 Padua, 7 Verona, ITALY
PRACTICAL GUIDELINES FOR THE MANAGEMENT OF PRIMARY
ALDOSTERONISM
14.07 ACE2 AND ANGIOTENSIN-(1-7) AND ALDOSTERONE
BIOSYNTHESIS IN HUMAN ADRENOCORTICAL TISSUES G.P. Rossi, V. Bisogni, M. Cesari, G. Maiolino, T.M. Seccia
B. Caroccia 1, P.-E. Vanderriele 1, T.M. Seccia 1, M. Piazza 1, L. Lenzini 1, Padua, ITALY
S. Prisco 1, F. Torressan 1, O. Domening 2, M. Poglitsch 2, M. Iacobone 1,
G.P. Rossi 1 14.49 GENES MEDIATING CELL GROWTH IN ALDOSTERONE-
1
Padua, ITALY, 2 Vienna, AUSTRIA PRODUCING ADENOMAS
Y. Yang 1, M. Tetti 2, P. Mulatero 2, H. Schneider 1, M. Reincke 1,
14.14 EFFECTS OF THE MTORC1 INHIBITOR EVEROLIMUS ON T.A. Williams 1,2
HEMODYNAMIC CHARACTERISTICS OF PATIENTS WITH PRIMARY 1
Munich, GERMANY, 2 Turin, ITALY
ALDOSTERONISM
T. Burkard, B. Trinh
Basel, SWITZERLAND
14.21 GLUCO- AND MINERALOCORTICOIDS SYNERGISTICALLY

DOWNREGULATE BKCA CHANNEL TRANSCRIPTION IN
VASCULAR SMOOTH MUSCLE CELLS BUT DO NOT AFFECT THE
EPOXYEICOSATRIENOIC ACID PATHWAY
H. Schneider 1, L. Fruehbuss 1, J. Sun 1, Y. Meng 1, J. Gonzales Marques 1,
B. Koletzko 1, M. Mederos Y. Schnitzler 1, T. Gudermann 1, F. Beuschlein 3,
T.A. Williams 1,2, M. Reincke 1
1
Munich, GERMANY, 2 Turin, ITALY, 3 Zurich, SWITZERLAND
62
14.00-15.00 - ROOM 2 14.00-15.00 - ROOM 3
Joint Session ESH-ISH-LASH Workshop

ADIPOSITY, MUSCULAR STRENGTH AND RENOVASCULAR HYPERTENSION
CARDIOMETABOLIC DISEASE: FROM FOETAL Chairpersons: P.W. de Leeuw (Maastricht, THE NETHERLANDS),
PROGRAMMING TO SARCOPENIA IN THE ELDERLY A. Persu (Brussels, BELGIUM)
Chairpersons: A. Coca (Barcelona, SPAIN),
A. Ramirez (Buenos Aires, ARGENTINA)
14.00-14.20 Diagnosis and management of atherosclerotic renal
artery stenosis
14.00-14.15 Muscular strength as predictor of future cardiovascular L. Amar (Paris, FRANCE)
disease
P. López-Jaramillo (Bucaramanga, COLOMBIA) 14.20-14.40 Should we screen for rare causes of renovascular
hypertension?
14.15-14.30 Sarcopenia and metabolic disorders A. Januszewicz (Warsaw, POLAND)
C. Borghi (Bologna, ITALY)
14.30-14.45 Relevance of sarcopenia in cardiovascular disease in
the elderly
J. Redon (Valencia, SPAIN)
63
14.00-15.00 - ROOM 4 14.00-15.00 - ROOM 5
Portuguese Session Workshop

HTA E RISCO CARDIOVASCULAR NOS PAÍSES DE TECHNOLOGICAL ADVANCES FROM LARGE TO
LÍNGUA PORTUGUESA/HTN AND CARDIOVASCULAR SMALL ARTERIES AND USEFULNESS IN
RISK IN PORTUGUESE SPEAKING COUNTRIES HYPERTENSION
Chairpersons: L. Bronze (Lisbon, PORTUGAL), Chairpersons: M. Cecelja (London, UNITED KINGDOM),
V. Paixão Dias (Vila Nova de Gaia, PORTUGAL) P. Cunha (Guimarães, PORTUGAL)
14.00-14.15 Risco Vascular e COVID-19 em África/Vascular risk and 14.00-14.20 What’s new in large and medium-sized arteries
COVID-19 in Africa R.M. Bruno (Paris, FRANCE)
14.20-14.40 What’s new in small arteries and microcirculation
14.15-14.30 O que há de novo na Diretriz Brasileira de Hipertensão C. Stehouwer (Maastricht, THE NETHERLANDS)
2020/What’s new on 2020 Brazilian Hypertension
Guidelines 14.40-15.00 Discussion
W. Sebba-Barroso (Goiania, BRAZIL)
14.30-14.45 Restrição do consumo de sal: qual o contributo

para o controlo da pressão arterial e prevenção
cardiovascular/Salt restriction: its role in pressure
control and cardiovascular health
F. Pinto (Santa Maria Feira, PORTUGAL)
64
14.00-14.45 - ROOM 6 15.00-17.00 - AUDITORIUM
Debate ESH Working Group on Blood Pressure

Monitoring and Cardiovascular Variability
ACCURATE MEASUREMENT OF BLOOD PRESSURE:
DO WE NEED TO DO BETTER? 2021 ESH PRACTICE BLOOD PRESSURE
Chairperson: J. Sharman (Hobart, AUSTRALIA) MONITORING GUIDELINES
14.00-14.15 Pro - We are doing well, there is no need to improve 15.00-15.10 Welcome and Objectives
methods R. Kreutz (Berlin, GERMANY),
P.K. Whelton (New Orleans, LA, USA) G. Mancia (Milan, ITALY),
14.15-14.30 Against - We are not doing well, there is a need to
improve methods 15.10-15.30 GENERAL ISSUES
J. Filipovsky (Pilsen, CZECH REPUBLIC) Chairpersons: K. Kario (Tochigi, JAPAN),
M.G. Myers (Toronto, CANADA)
15.10-15.20 BP measuring devices - arm/wrist cuff and cuffless
Comments
G. Head (Melbourne, AUSTRALIA)
15.20-15.30 Cuff issues - blood pressure variability issues

P. Palatini (Padua, ITALY)
Comments
G. Bilo (Milan, ITALY)
15.30-16.00 CLASSIC BP MEASUREMENT METHODS

Chairpersons: T. Niiranen (Turku, FINLAND),
J. Wang (Shanghai, CHINA)
15.30-15.40 Office BP measurement

R. Asmar (Paris, FRANCE)
Comments
M.G. Myers (Toronto, CANADA)
65
15.40-15.50 Ambulatory BP monitoring 16.30-16.40 How to detect white coat and masked hypertension in
E. O’Brien (Dublin, IRELAND) clinical practice?
Comments K. Kario (Tochigi, JAPAN),
E. Manios (Athens, GREECE) R. McManus (Oxford, UNITED KINGDOM),
J. Sharman (Hobart, AUSTRALIA)
15.50-16.00 Home BP monitoring and telemonitoring
G. Parati (Milan, ITALY) 16.40-16.50 How to detect non-dippers in clinical practice?
Comments A. De la Sierra (Barcelona, SPAIN),
S. Omboni (Varese, ITALY) A. Kollias (Athens, GREECE),
J. Wang (Shanghai, CHINA)
16.00-16.10 OTHER BP MEASUREMENT METHODS
Chairpersons: E. Dolan (Dublin, IRELAND), 16.50-17.00 Conclusions and Closing
T. Ohkubo (Sendai, JAPAN) E. O’Brien (Dublin, IRELAND),
16.00-16.10 BP measurement in pharmacies/kiosks
R. McManus (Oxford, UNITED KINGDOM)
Comments
K. Asayama (Tokyo, JAPAN)
16.10-16.50 MANAGEMENT OF HYPERTENSION IN PRACTICE -

EXPERT OPINIONS
Chairpersons: P. Palatini (Padua, ITALY),
16.10-16.20 How to make accurate diagnosis in clinical practice?

J. Filipovsky (Pilsen, CZECH REPUBLIC),
T. Ohkubo (Sendai, JAPAN),
16.20-16.30 How to titrate treatment and follow-up in clinical

practice?
K. Asayama (Tokyo, JAPAN),
T. Niiranen (Turku, FINLAND),
A. Mihailidou (Kensington, AUSTRALIA)
66
15.00-16.00 - ROOM 1
15.28 BLOOD PRESSURE LOWERING EFFECTS AND SAFETY
Oral Session 11A OF ESEXERENONE, NEWLY AVAILABLE MINERALOCORTICOID
RECEPTOR BLOCKER
F. Satoh, R. Morimoto, Y. Tezuka, K. Omata, H. Yamanami, Y. Ono, S. Ito
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Sendai, JAPAN
Chairpersons: A. Persu (Brussels, BELGIUM),
R. Wainford (Boston, MA, USA) 15.35 TELMISARTAN IMPROVES MYOCARDIAL REMODELING IN
RATS WITH HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY
THROUGH INHIBITING LEPTIN AUTOCRINE INDUCED BY ANGII
15.00 DOCA-SALT DIMINISHES BRAIN RAS ACTIVITY IN AND ACTIVATING PPAR GAMMA
PARALLEL WITH PLASMA AND RENAL RAS ACTIVITY – NO H. Chen, M. Li, L. Liu, D. Zhu, G. Tian
EVIDENCE FOR SELECTIVE BRAIN RAS ACTIVATION Xi’an, CHINA
E. Uijl 1, L. Ren 1, K.M. Mirabito Colafella 2, M. Poglitsch 3, O. Domenig 3,
I. Zlatev 4, J.B. Kim 4, S. Huang 4, L. Melton 4, D. Foster 4, A.H. Jan Danser 1 15.42 PROXIMAL TUBULE-SPECIFIC DELETION OF AT1A
1
Rotterdam, THE NETHERLANDS, 2 Melbourne, AUSTRALIA, 3 Vienna, RECEPTORS ATTENUATES ANGIOTENSIN II-INDUCED
AUSTRIA, 4 Cambridge, MA, USA
HYPERTENSION BY INCREASING GLOMERULAR FILTRATION
AND THE PRESSURE-NATRIURESIS RESPONSE
15.07 ESTABLISHMENT OF A NEW SPECIFIC HIGH SENSITIVITY
MEASUREMENT SYSTEM FOR SOLUBLE ANGIOTENSIN IV X. Li 1, A. Leite 1, X. Zheng 2, C. Zhao 2, J. Zhuo 1
RECEPTOR
1
New Orleans, LA, USA, 2 Nanning, CHINA
T. Konoshita 1, S. Azuma 1, M. Sugiyama 1, M. Furutani 1, S. Kaeriyama 1,
R. Saito 1, S. Sato 1, M. Imagawa 1, Y. Zenimaru 1, J. Suzuki 1, M. Fujii 1, 15.49 RECEPTOR INTERACTING MOLECULE ATRAP AS
Y. Makino 2 MODULATOR OF RENAL SODIUM HANDLING AND PATHOLOGICAL
1
Fukui, 2 Tsuruga, JAPAN BLOOD PRESSURE RESPONSE
K. Tamura, T. Yamaji, S. Kinguchi, R. Kobayashi, K. Azushima, K. Uneda,
15.14 DISTRIBUTION OF RENIN-ANGIOTENSIN-ALDOSTERONE K. Haruhara, T. Kanaoka, S. Urate, E. Abe, S. Tanaka, T. Ishii, T. Kumagai,
SYSTEM (RAAS) BIOMARKERS IN TREATED HYPERTENSIVE A. Yamashita, H. Wakui
INDIVIDUALS FROM THE GENERAL POPULATION: THE CHRIS Yokohama, JAPAN
STUDY
L. Foco 1, M. Poglitsch 2, M. Gögele 1, P.P. Pramstaller 1, C. Pattaro 1
1
Bolzano, ITALY, 2 Vienna, AUSTRIA
15.21 ANGIOTENSIN AT2 RECEPTORS IN THE NUCLEUS OF THE

SOLITARY TRACT REDUCE BLOOD PRESSURE VIA INHIBITION OF
GABA SIGNALING
M. Mohammed, C. Sumners, D. Johnson, K. Scott, E. Krause,
A. de Kloet, K. Elsaafien
Gainesville, FL, USA
67
15.00-16.00 - ROOM 2 15.00-16.00 - ROOM 3
Clinical Cases Topical Workshop

CLINICAL-PATHOLOGICAL CONFERENCE (CPC) THE GLOBAL BATTLE AGAINST HYPERTENSION -
IN COOPERATION WITH HYPERTENSION, AN THE LANCET COMMISSION ON HYPERTENSION AND
AMERICAN HEART ASSOCIATION JOURNAL CDC
(AHA) Chairpersons: A. Schutte (Sydney, AUSTRALIA),
Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM), S. Spencer (London, UNITED KINGDOM)
15.00-15.20 Where medicine went wrong

15.00-15.20 Case 1 - Borderline and Hypertension
S. Leopold (Houston, TX, USA), 15.20-15.22 The Lancet Commission: Four years into fighting
J.P. Zachariah (Houston, TX, USA) hypertension
M.H. Olsen (Holbæk, DENMARK)
15.22-15.27 A call for blood pressure device validation
15.30-15.50 Case 2 - Hypertension related to catecholamine excess J. Sharman (Hobart, AUSTRALIA)
A.-G. Lopez (Rouen, FRANCE),
15.27-15.32 A digital management system for hypertension in rural
L. Amar (Paris, FRANCE) India
A. More (Latur, INDIA)
15.32-15.34 CDC in the battle against hypertension
Q. Mukhtar (Atlanta, GA, USA)
15.34-15.39 Trends and disparities of CVD burden for 37 countries

of the Americas
R. Martinez (Washington, DC, USA)
15.39-15.44 India Hypertension Control Initiative - Hypertension

treatment and blood pressure control in a cohort in 24
sentinel site clinics, India
J. Mitra (Tamjil Nadu, INDIA)
Q. Mukhtar (Atlanta, GA, USA), M.H. Olsen (Holbæk,
DENMARK), N.R. Poulter (London, UNITED KINGDOM)
68
15.00-16.00 - ROOM 4 15.00-16.00 - ROOM 5
ISH Regional Advisory Group for Middle Meet the expert

East North Africa - First Scientific
LOST IN TRANSLATION - IS ‘FROM BENCH TO
International Society of Hypertension BEDSIDE’ THE HOLY GRAIL?
Middle East North Africa Chairperson: G.P. Rossi (Padua, ITALY)
HYPERTENSION MANAGEMENT IN THE MIDDLE

EAST AND NORTH AFRICA 15.00-15.20 Lost in translation - a case for curiosity
T. Unger (Maastricht, THE NETHERLANDS)
Chairpersons: T. Albassam (AlKhoba, SAUDI ARABIA),
G. Haji (Baghdad, IRAQ),
15.20-15.40 Enhancing the alternative RAS: from concept to
A. Stanley (Dubai, UNITED ARAB EMIRATES)
compound
L. Paulis (Bratislava, SLOVAK REPUBLIC)
15.00-15.05 Opening Remarks
J. Al Said (Manama, BAHRAIN)
15.05-15.20 Which Guidelines are more suitable for our patients?

A. Shehab (Al Ain, UNITED ARAB EMIRATES)
15.20-15.35 Hypertension epidemiology in the Middle East and

North Africa
R. El Bikai (Balamand, LEBANON)
15.35-15.50 Hypertension among children in the Middle East and

North Africa
J. Al Said (Manama, BAHRAIN)
69
15.00-16.00 - ROOM 6
Oral Session 11B 15.28 DNA REPAIR DEFECT IN SMOOTH MUSCLE CELL
REPRODUCES FEATURES OF AGE-RELATED VASCULAR DISEASE
IN MICE
AGEING
E. Ataei Ataabadi 1, K. Golshiri 1, R. De Vries 1, G.L. Snyder 2, L. Zhang 2,
Chairpersons: A. Benetos (Nancy, FRANCE), P. Li 2, R.E. Davis 2, A.H.J. Danser 1, A.J.M. Roks 1
B. Wynne (Salt Lake City, UT, USA) 1
Rotterdam, THE NETHERLANDS, 2 New York, NY, USA
15.35 CHARACTERISTICS OF HEALTHY VASCULAR AGEING (HVA)

15.00 ASSOCIATION BETWEEN THE DIFFERENCE OF BILATERAL AND EARLY VASCULAR AGEING (EVA) IN GENERAL POPULATION.
BRACHIAL-ANKLE PULSE WAVE AND CARDIOVASCULAR EVENTS, EH-UH STUDY (CROATIAN SCIENTIFIC FOUNDATION)
ALL-CAUSE MORTALITY M. Marinovic Glavic 1, L. Blagus 2, V. Bosnjak 2, S. Frkanec 2, L. Katic 2,
M. Zheng, S. Wu V. Domislovic 2, M. Matasin 2, J. Kos 2, T. Zeljkovic Vrkic 2, I. Pecin 2,
Tangshan, CHINA A. Jelakovic 2, V. Premuzic 2, Z. Dika 2, S. Karanovic 2, V. Kriksic 2,
K. Capak 2, R. Stevanovic 2, B. Jelakovic 2
15.07 VASCULAR AGING INDEPENDENTLY PREDICTS ALL-CAUSE 1
Rijeka, 2 Zagreb, CROATIA
MORTALITY IN THE HEINZ NIXDORF RECALL STUDY
T. Weber 1, S. Wassertheurer 2, B. Hametner 2, C. Mayer 2, S. Moebus 3, 15.42 RELATIONSHIP BETWEEN VASCULAR AGEING AND
S. Schramm 3, U. Roggenbuck 3, N. Lehmann 3, K.-H. Joeckel 3, R. Erbel 3 LEFT VENTRICULAR CONCENTRIC GEOMETRY IN COMMUNITY-
1
Wels, 2 Vienna, AUSTRIA, 3 Essen, GERMANY DWELLING ELDERLY: THE NORTHERN SHANGHAI STUDY
R. Maimaitiaili, J. Teliewubai, S. Zhao, J. Tang, C. Chi, Y. Zhang, Y. Xu
15.14 EPIDEMIOLOGICAL CHARACTERISTICS AND RELATED Shanghai, CHINA
FACTORS OF FRAILTY IN CHINESE OLDER ADULTS WITH
HYPERTENSION 15.49 PREVALENCE AND PREDICTORS OF HYPOTENSION IN
L. Ma, Y. Li, Z. Tang NURSING HOME RESIDENTS UNDERGOING AMBULATORY BLOOD
Beijing, CHINA PRESSURE MONITORING
G. Rivasi, V. Tortù, M.F. D’Andria, G. Turrin, E. Giuliani, L. Ceolin,
15.21 THE EFFECTS OF ITI-214 (A NEW PHOSPHODIESTERASE M. Rafanelli, E. Mossello, A. Ungar
1 INHIBITOR) ON VASCULAR AGEING FEATURES ASSOCIATED TO Florence, ITALY
DNA REPAIR RESPONSE IN MICE
K. Golshiri 1, E. Ataei 1, R. De Vries 1, R. Van Veghel 1, G.L. Snyder 2,
L. Zhang 2, P. Li 2, R.E. Davis 2, A.H.J. Danser 1, A.J.M. Roks 1
1
Rotterdam, THE NETHERLANDS, 2 New York, NY, USA
70
16.00-16.45 - ROOM 1 16.00-17.00 - ROOM 2
Minisymposium ISH Americas Regional Advisory Group

supported by Vifor Pharma Session
OVERCOMING CHALLENGES IN MANAGEMENT OF HYPERTENSION IN THE AMERICAS
PATIENTS WITH RESISTANT HYPERTENSION AND
Chairpersons: C. Romero (Atlanta, GA, USA),
CKD M. Tomaszewski (Manchester, UNITED KINGDOM)
Chairperson: L.M. Ruilope (Madrid, SPAIN)
16.00-16.05 ISH Americas RAG introduction and objectives

16.00-16.05 Introduction C. Romero (Atlanta, GA, USA)
16.05-16.20 Three Americas: an overview on hypertension status
16.05-16.15 Challenges in management of resistant hypertension in and research across the Americas
patients with CKD D. Piskorz (Rosario, ARGENTINA)
16.20-16.35 Social determinants of health and inequalities in
16.15-16.35 Patiromer vs placebo to enable spironolactone in hypertension in the Americas
patients with resistant hypertension and chronic D. Lucumi (Bogotá, COLOMBIA)
kidney disease (AMBER): primary results and results in
prespecified subgroups 16.35-16.50 Addressing awareness and hypertension control in
B. Williams (London, UNITED KINGDOM) Latin America: tips for primary care physicians and
policy makers
16.35-16.45 Panel discussion & summary E. Muxfeldt (Rio de Janeiro, BRAZIL)
71
16.00-17.00 - ROOM 3
16.28 87 RARE VARIANTS ASSOCIATED WITH BLOOD PRESSURE
Oral Session 12A IN META-ANALYSIS OF ~1.32 MILLION INDIVIDUALS
E. Feofanova
Houston, TX, USA
BIG DATA AND e-HEALTH
Chairpersons: H. Itoh (Tokyo, JAPAN), 16.35 MACHINE LEARNING CLUSTERING FOR BLOOD PRESSURE
M. Viigimaa (Tallinn, ESTONIA) VARIABILITY: VALIDATION FROM THE SPRINT TO THE HONG KONG
COMMUNITY COHORT
K. Tsoi 1, N. Chan 1, K. Yiu 1, S. Poon 2, K. Ho 3, B. Lin 4
16.00 COMPARATIVE EFFECTIVENESS OF 1
Shatin, HONG KONG, 2 Sydney, AUSTRALIA, 3 Vancouver, CANADA,
HYDROCHLOROTHIAZIDE VERSUS CHLORTHALIDONE ON 4
California, UNITED STATES MINOR OUTLYING ISLANDS
CARDIAC, RENAL AND ELECTROLYTE EVENTS BY EGFR STAGE
C. Edwards, W. Petrcich, G. Hundemer, E. Clark, G. Knoll, M. Ruzicka, 16.42 LECTURE
E. Rhodes, K. Burns, M. Sood PERSONALIZED APPROACHES TO HYPERTENSION:
Ottawa, CANADA OPPORTUNITIES AND OBSTACLES
D. Arnett (Lexington, KY, USA)
16.07 MACHINE LEARNING BASED MODELS FOR PREDICTING
WHITE-COAT AND MASKED PATTERNS OF BLOOD PRESSURE
S. Lip 1, L. McCallum 1, S. Reddy 2, N. Chandrasekaran 3, S. Tule 3,
R.K. Bhaskar 3, S. Padmanabhan 1
1
Glasgow, UNITED KINGDOM, 2 Geelong, 3 Canberra, AUSTRALIA
16.14 APPLYING WEIGHTED PULSE DECOMPOSITION

ANALYSIS WITH SIGNAL QUALITY INDEX TO FINGER
PHOTOPLETHYSMOGRAM FOR ESTIMATION OF BLOOD
PRESSURES
T.-D. Wang 1, J.-W. Guo 2, P.-Y. Tsai 2, H.-J. Lin 1, A.-Y. Wu 1
1
Taipei City, 2 Taoyuan, TAIWAN
16.21 URINARY METABOLIC PHENOTYPE OF BLOOD PRESSURE

J.M. Posma 1, J. Stamler 2, I. Garcia-Perez 1, Q. Chan 1, A. Wijeyesekera 3,
M. Daviglus 2, L. Van Horn 2, E. Holmes 4, J. Nicholson 4, P. Elliott 1
1
London, UNITED KINGDOM, 2 Chicago, IL, USA, 3 Reading, UNITED
KINGDOM, 4 Perth, AUSTRALIA
72
16.00-17.00 - ROOM 4
16.43 PULSE WAVE REFLECTION AND GENDER DIFFERENCE IN
Oral Session 12B OBESE INDIVIDUALS
Z. Junli 1, C. Huijuan 1, A. Audrey 2, A. Alberto 2, M. Orourke 2
1
Shanghai, CHINA, 2 Sydney, AUSTRALIA
OBESITY AND METABOLIC SYNDROME
Chairpersons: A.J. Manolis (Athens, GREECE), 16.50 THE ASSOCIATION OF CALF CIRCUMFERENCE AND ALL-
F. Marques (Melbourne, AUSTRALIA) CAUSE, CARDIOVASCULAR AND CEREBROVASCULAR MORTALITY:
RESULTS FROM THE NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEYS
16.00 LECTURE J. Huang, L. Liu, C. Chen, Y. Huang, G. Shen, Y. Yu, Y. Feng
MICROBES AND METABOLITES: WHAT IS THE PRESSURE? Guangzhou, CHINA
B. Joe (Toledo, OH, USA)
16.15 THIGH CIRCUMFERENCE AND RISK OF ALL-CAUSE,

CARDIOVASCULAR AND CEREBROVASCULAR MORTALITY:
RESULTS FROM THE NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEY 1999-2006
C.-L. Chen 1, J.-Y. Huang 1, L. Liu 1, Y.-L. Yu 1, G. Shen 1, K. Lo 2,
Y.-Q. Huang 1, Y.-Q. Feng 1
1
Guangzhou, CHINA, 2 Providence, RI, USA
16.22 METFORMIN AND LOSARTAN PREVENT PERIVASCULAR

ADIPOSE TISSUE ALTERATIONS AND PROSTANOIDS RELEASE IN A
MODEL OF METABOLIC SYNDROME IN THE RAT
A.M. Puyó, H.J. Lee, A.S. Donoso, S.M. Cantú, H.A. Peredo, M.R. Choi
16.29 EFFECT OF OBESITY ON VENTRICULAR MASS INDEX

AND DIASTOLIC DYSFUNCTION IN YOUNG PATIENTS WITH
HYPERTENSION
X. Chen, X. Zhang, J. Yu
Lanzhou, CHINA
16.36 DYNAMIC CHANGES IN CHILD-TO-ADULT BODY MASS

INDEX AND METABOLIC SYNDROME IN MIDDLE AGE: 30-YEAR
HANZHONG ADOLESCENT HYPERTENSION STUDY
Y. Yuan, I.-J. Mu, C. Chu, W.-L. Zheng, Y. Wang, Q. Ma, J.-W. Hu, Y. Yan,
Y.-Y. Liao, C. Chen
Xi’an, CHINA
73
16.00-17.00 - ROOM 5
16.28 DIETARY INFLUENCE OF SYSTOLIC AND DIASTOLIC
Oral Session 12C BLOOD PRESSURE IN THE TWINSUK COHORT
P. Louca 1, S.E. Berry 1, T.D. Spector 1, S. Padmanabhan 2, C. Menni 1
1
London, 2 Glasgow, UNITED KINGDOM
BLOOD PRESSURE VARIABILITY
Chairpersons: G. Grassi (Milan, ITALY), 16.35 SEASONAL VARIATION OF MASKED UNCONTROLLED
J. Wang (Shanghai, CHINA) NOCTURNAL HYPERTENSION MEASURED BY NIGHTIME HOME
BLOOD PRESSURE: THE J-HOP NOCTURNAL BLOOD PRESSURE
STUDY
16.00 INTENSIVE TREATMENT IS SUITABLE FOR PATIENTS WITH K. Narita, S. Hoshide, K. Kario
LOW LEVEL OF BLOOD PRESSURE VARIABILITY: A SECONDARY 1
Shimotsuke, 2 Karatsu, JAPAN
ANALYSIS OF SPRINT
K. Tsoi, K. Yiu, K. Sit, E. Lee, S. Wong 16.42 FIRST RESULTS OF THE NEW HUNGARIAN HYPERTENSION
Shatin, HONG KONG REGISTRY: SEASONAL CHANGES OF BLOOD PRESSURE VALUES
D. Páll 1, J. Nemcsik 2, N. Habony 2, C. Farsang 2, G. Ábrahám 3, A. Simon 4,
16.07 DIPPING PATTERN AND SHORT-TERM BLOOD PRESSURE B. Benczúr 5, Z. Járai 2
VARIABILITY ARE STRONGER PREDICTORS OF CARDIOVASCULAR 1
Debrecen, 2 Budapest, 3 Szeged, 4 Balatonfüred, 5 Szekszárd, HUNGARY
EVENTS THAN AVERAGE 24-HOUR BLOOD PRESSURE IN
HYPERTENSION OF THE YOUNG 16.49 A NOVEL DEFINITION, EARLY EVENING ELEVATED BLOOD
P. Palatini 1, P. Reboldi 2, F. Saladini 1, F. Angeli 2, L. Mos 3, C. Fania 1, PRESSURE, HAS A HIGH PREVALENCE RATE ACCORDING TO
A. Mazzer 4, O. Vriz 3, P. Verdecchia 2 AMBULATORY BLOOD PRESSURE MONITORING
1
Padua, 2 Perugia, 3 San Daniele del Friuli, 4 Vittorio Veneto, ITALY Z. Ma, Y. Zhao, X. Lu, F. Yang, Y. Chen, N. Sun
Beijing, CHINA
16.14 SEASONAL VARIATION OF NIGHTTIME HOME BLOOD
PRESSURE AND ITS ASSOCIATION WITH TARGET ORGAN
DAMAGE: THE J-HOP NOCTURNAL BLOOD PRESSURE STUDY
K. Narita, S. Hoshide, K. Kario
1
16.21 DIURNAL RHYTHM AND SALT RESPONSIVE RESHAPING OF

GUT MICROBIOTA CORRELATES WITH HYPERTENSION
J. Mandal, S. Chakraborty, X. Cheng, S. Galla, A. Hindupur, P. Saha,
B. San Yeoh, B. Mell, J.-Y. Yeo, M. Vijay-Kumar, T. Yang, B. Joe
Toledo, OH, USA
74
16.00-17.00 - ROOM 6
Workshop
HYPERTENSIVE EMERGENCIES MANAGEMENT
Chairpersons: J. Brguljan (Ljubljana, SLOVENIA),
L. Ghiadoni (Pisa, ITALY)
16.00-16.20 Hypertension in acute heart failure

M.L. Muiesan (Brescia, ITALY)
16.20-16.40 Malignant Hypertension

A. Cremer (Bordeaux, FRANCE)
75
WEDNESDAY, APRIL 14 SCIENTIFIC PROGRAMME
11.00-12.00 - AUDITORIUM 11.00-12.00 - ROOM 1
Topical Workshop on Hot Issues World Hypertension League

ARE ELECTRONIC CIGARETTES A FAVOURABLE IMPLEMENTING THE CALL TO ACTION FOR GLOBAL
ALTERNATIVE TO SMOKING IN CARDIOVASCULAR HYPERTENSION CONTROL
PATIENTS? Chairpersons: D.T. Lackland (Charleston, WV, USA),
Chairpersons: M. Burnier (Lausanne, SWITZERLAND), C. Varghese (Geneva, SWITZERLAND)
C. Delles (Glasgow, UNITED KINGDOM)
11.00-11.08 The call and objectives with success stories

11.00-11.02 Welcome and introduction N. Campbell (Toronto, CANADA)
C. Delles (Glasgow, UNITED KINGDOM)
11.08-11.16 Establishing the essential collaborations
11.02-11.17 Tobacco control and electronic cigarettes: is there a G. Parati (Milan, ITALY)
new epidemic?
L. Bauld (Edinburgh, UNITED KINGDOM) 11.16-11.24 Announcing and promotion of the call
X.-H. Zhang (Urumqi, CHINA)
11.17-11.32 Cardiovascular effects of electronic cigarettes: what is
the evidence? 11.24-11.32 Incorporating the regional and local attributes
K. Franzen (Lubeck, GERMANY) M. Orias (Cordoba, ARGENTINA)
11.32-11.47 Pulmonary effects of electronic cigarettes: vaping- 11.32-11.40 Incorporating health care systems and providers in the
associated pulmonary disease call
M. Chaumont (Brussels, BELGIUM) V.S. Ram (Hyderabad, INDIA)
11.47-12.00 Panel discussion 11.40-11.48 Evaluating the impact of the call

P.K. Whelton (New Orleans, LA, USA)
11.48-12.00 Questions and Answers
78
11.00-12.00 - ROOM 2 11.00-12.00 - ROOM 3
Workshop Workshop
ENVIRONMENTAL POLLUTION AND HYPERTENSION CVD DETECTION, PREVENTION AND CONTROL IN
Chairpersons: D. Prabhakaran (Gurugram, INDIA), LOW- AND MIDDLE-INCOME COUNTRIES: FIELD
M. Rajzer (Krakov, POLAND) EPIDEMIOLOGY TRAINING PROGRAM (FETP)
STORIES FROM THE FIELD
Chairpersons: Q. Mukhtar (Atlanta, GA, USA),
11.00-11.20 Environmental pollution and hypertension
A. Moran (New York, NY, USA)
11.20-11.40 Pesticides and cardiometabolic dysfunction

11.00-11.07 Enhancing hypertension diagnosis in a hospital setting
L. Jaacks (Edinburgh, UNITED KINGDOM)
in Thailand
K. Yueayai (Mueang Nakhon Ratchasima, THAILAND)
11.09-11.16 A perspective of private health care providers in

Madhya Pradesh on adopting key strategies of the
India Hypertension Control Initiative
A. Krishna (Gurugram, INDIA)
11.18-11.25 Factors related to medication adherence among

known hypertensive adults in Yaounde central region in
Cameroon, 2019 prevention and challenge
A.M. Mengue Essindi (Yaounde, CAMEROON)
79
11.00-12.00 - ROOM 4
11.27-11.34 Assessing service availability and readiness of health
facilities to offer hypertension diagnosis services in Oral Session 13A
Wakiso District, Uganda
J. Nanono (Kampala, UGANDA)
LIFESTYLE CHANGES/LIPIDS/SALT
11.34-11.36 Discussion Chairpersons: P. López-Jaramillo (Bucaramanga, COLOMBIA),
J. Polonia (Porto, PORTUGAL)
11.36-11.43 FETP Resident/Small Grant Recipient
A. Musyani (Dar es Salaam, TANZANIA)
11.00 HIGH SODIUM INTAKE INDUCES A CATABOLIC STATE
11.43-11.45 Discussion VIA GLOMERULAR HYPERFILTRATION AND ENHANCED
GLOMERULOTUBULAR BALANCE IN PATIENTS WITH ESSENTIAL
11.45-12.00 General Discussion HYPERTENSION
G. Rossitto 1, G. Maiolino 2, S. Lerco 2, G. Ceolotto 2, G. Blackburn 1,
S. Mary 1, G. Antonelli 2, C. Berton 2, V. Bisogni 2, M. Cesari 2, T.M. Seccia 2,
L. Lenzini 2, A. Montezano 1, R. Touyz 1, M.C. Petrie 1, R. Daly 1, P. Welsh 1,
M. Plebani 2, G.P. Rossi 2, C. Delles 1
1
Glasgow, UNITED KINGDOM, 2 Padua, ITALY
11.07 A RANDOMIZED CONTROLLED TRIAL OF LIFE-

MODIFICATION INTERVENTION FOCUSED ON REDUCING
ALCOHOL INTAKE TO CONTROL THE HYPERTENSION IN MALE
PATIENTS DURING OUTPATIENT VISIT: OSAKE STUDY
M. Kabayama 1, Y. Akagi 1, M. Tamatani 2, J. Tomita 3, S. Takiuchi 4,
K. Yamamoto 1, K. Sugimoto 1, H. Rakugi 1, K. Kamide 1
1
Suita, 2 Osaka, 3 Toyonaka, 4 Takarazuka, JAPAN
11.14 BENEFICIAL EFFECTS OF WEEKLY WALKING ACTIVITY ON

HYPERTENSIVE MEDIATED ORGAN DAMAGE IN THE COMMUNITY-
DWELLING ELDERLY CHINESE: THE NORTHERN SHANGHAI STUDY
Y. Lyu, Y. Zhang, C. Chi, S. Yu, Y. Xu
Shanghai, CHINA
11.21 SODIUM CONSUMPTION QUESTIONNAIRE WITH

PHOTOGRAPHIC MANUAL: DEVELOPMENT OF A NEW TOOL FOR
EVALUATION OF HYPERTENSIVE OUTPATIENTS
L. Bortolotto, B. Cardoso, A. Duenhas
Sao Paulo, BRAZIL
80
11.00-13.00 - ROOM 5
11.28 ASSESSING THE EFFICACY OF A 90 DAY GLUTEN-
FREE DIET ON CHANGE IN WEIGHT AND ANTHROPOMETRY IN Live Session
HYPERTENSIVE MALES
M. Patil, V. Patil
BASICS OF RENAL ULTRASOUND IN HYPERTENSIVE
Pune, INDIA
PATIENTS. AN INITIATIVE OF THE “ESH-SIEMENS
11.35 REDUCTION OF ALCOHOL CONSUMPTION CAN DECREASE EDUCATIONAL IMAGING PROGRAM”
HOME MORNING BLOOD PRESSURE IN MALE HYPERTENSIVE Chairpersons: A. Januszewicz (Warsaw, POLAND),
PATIENTS - OSAKE STUDY A. Persu (Brussels, BELGIUM),
Y. Akagi 1, M. Kabayama 1, M. Tamatani 2, J. Tomita 3, S. Takiuchi 4, M. Pruijm (Lausanne, SWITZERLAND)
K. Yamamoto 1,4, K. Sugimoto 1, H. Rakugi 1, K. Kamide 1
1
Suita, 2 Osaka, 3 Toyonaka, 4 Takarazuka, JAPAN
11.00-11.15 Technical basics of renal ultrasound and normal
11.42 LECTURE findings
BLOOD PRESSURE AND CARDIOVASCULAR RISK: A POPULATION- S. Arampatzis (Bern, SWITZERLAND)
BASED PERSPECTIVE
R. Collins (Oxford, UNITED KINGDOM) 11.15-11.30 Common abnormalities of the urogenital tract (renal
masses, nephrolithiasis, hydronephrosis)
M. Pruijm (Lausanne, SWITZERLAND)
11.30-11.45 Renal duplex ultrasound: atherosclerotic renal artery

stenosis and fibromuscular dysplasia
B. Ponte (Geneve, SWITZERLAND)
11.45-12.00 Q&A session
12.00-13.00 Live practical demonstration with possibility to interact

with the experts
M. Januszewicz (Warsaw, POLAND)
81
12.00-13.00 - AUDITORIUM 12.00-13.00 - ROOM 1
Teaching Seminar How-to Session (ISH Session)

SESSION 3 WOMEN IN HYPERTENSION RESEARCH -
Chairpersons: E. Agabiti Rosei (Brescia, ITALY), MAXIMISING OPPORTUNITIES AND REACHING
S. Erdine (Istanbul, TURKEY) CAREER GOALS
Chairpersons: M. Patil (Pune, INDIA),
12.00-12.15 Is the prevalence of arrhythmias really higher in
hypertension or is it only a coincidence?
A.J. Manolis (Athens, GREECE) 12.00-12.05 Women in Hypertension and Women in ISH
12.15-12.30 Baroreflex stimulation in resistant hypertension
P.W. de Leeuw (Maastricht, THE NETHERLANDS) 12.05-12.20 How I got to where I am today - opportunities and
challenges as a clinician scientist
12.30-12.45 Is there still any place for central antihypertensive R.M. Touyz (Glasgow, UNITED KINGDOM)
drugs?
S. Laurent (Paris, FRANCE) 12.20-12.35 Mid-career challenges of a female’s career in
hypertension research
12.45-13.00 Discussion N. Khan (Vancouver, CANADA)
82
12.00-13.00 - ROOM 2 12.00-13.00 - ROOM 3
Workshop Meet-the-expert
NUTRITION, MICROBIOMA AND CARDIOVASCULAR HOW TO DO A GOOD META-ANALYSIS OF OUTCOME
RISK RANDOMIZED TRIALS IN HYPERTENSION?
Chairpersons: F.P. Cappuccio (Warwick, UNITED KINGDOM), Chairpersons: B. Carlberg (Umeå, SWEDEN),
T. Unger (Maastricht, THE NETHERLANDS) G. Mancia (Milan, ITALY)
12.00-12.20 Microbiome and cardiovascular risk: the gut-heart axis? 12.00-12.20 Which trials to include and exclusion criteria
C. Reinhardt (Mainz, GERMANY) C. Thomopoulos (Athens, GREECE)
12.20-12.40 Plant-based diets and cardiovascular risk: population- 12.20-12.40 How to clinically report the synthesis and how to avoid
based evidence of benefit? mistakes?
B. Kappel (Aachen, GERMANY) M. Brunström (Umeå, SWEDEN)
12.40-13.00 Discussion 12.40-13.00 Discussion
83
12.00-13.00 - ROOM 4
12.28 ASSESSMENT OF CARDIOVASCULAR EVENTS IN
Oral Session 14A HYPERTENSIVE PATIENTS AT RISK FOR HEART FAILURE USING
GERIATRIC NUTRITIONAL RISK INDEX
T. Hashizume 1, M. Arita 2
ATRIAL FIBRILLATION AND HEART FAILURE 1
Tanabe, 2 Wakayama, JAPAN
Chairpersons: S.E. Kjeldsen (Oslo, NORWAY),
A. Prejbisz (Warsaw, POLAND) 12.35 CLINICAL AND ECHOCARDIOGRAPHIC FEATURES OF
PATIENTS WITH HEART FAILURE WITH MID-RANGE EJECTION
FRACTION COMPARED TO REDUCED AND PRESERVED
12.00 BLOOD PRESSURE LOWERING TREATMENT FOR M. Biolcati, A. Maloberti, S. Bianchi, V. Giani, C. Pellegrinelli, U. Ceratti,
PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH O. Belli, F. Casadei, F. Musca, P. Sormani, G. Santambrogio, F. Spanò,
ATRIAL FIBRILLATION: AN INDIVIDUAL-PARTICIPANT DATA B. de Chiara, C. Giannattasio, A. Moreo
META-ANALYSIS Milan, ITALY
A.C. Pinho-Gomes 1, L. Azevedo 3, E. Copland 1, D. Canoy 1,2,
M. Nazarzadeh 1, R. Ramakrishnan 1,2, E. Berge 4, J. Sundstrom 5, 12.42 EFFECT OF BLOOD PRESSURE OPTIMISATION ON
D. Kotecha 6, M. Woodward 1,2, K. Rahimi 1 ENDOTHELIAL FUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION
1
Oxford, UNITED KINGDOM, 2 Sydney, AUSTRALIA, 3 Porto, PORTUGAL, AND HYPERTENSION
4
Tromson, NORWAY, 5 Uppsakla, SWEDEN, 6 Birmingham, UNITED
A.A. Khan 1, G.N. Thomas 1, G. Lip 2
KINGDOM 1
Birmingham, 2 Liverpool, UNITED KINGDOM
12.07 EFFECT OF RENAL DENERVATION ON ATRIAL
12.49 BLOOD PRESSURE AT ADMISSION PREDICTS 1-YEAR
FIBRILLATION (ERDAF)
P. Papakonstantinou, D. Konstantinidis, I. Leontsinis, P. Iliakis, K. Tsioufis OUTCOMES OF PATIENTS HOSPITALIZED FOR HEART FAILURE
Athens, GREECE X. Huang, J. Liu, S. Hu, J. Li
Beijing, CHINA
12.14 GENETIC SUSCEPTIBILITY, ELEVATED BLOOD PRESSURE
AND RISK OF ATRIAL FIBRILLATION
M. Nazarzadeh 1, A.-C. Pinho-Gomes 1, Z. Bidel 1, D. Canoy 1,2,
A. Dehghan 3, K. Smith Byrne 1, D.A. Bennett 1, G.D. Smith 4, K. Rahimi 1
1
Oxford, UNITED KINGDOM, 2 Sydney, AUSTRALIA, 3 London,
4
Bristol, UNITED KINGDOM
12.21 COMBINATION OF SYSTOLIC BLOOD PRESSURE AND

NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IS A MAJOR
COMPONENT OF THE RISK SCORE FOR LATENT HEART
FAILURE: THE SUITA STUDY
Y. Kokubo, A. Higashiyama, M. Watanabe, K. Honda-Kohmo, Y. Miyamoto
Suita, JAPAN
84
13.00-14.00 - AUDITORIUM 13.00-14.00 - ROOM 1
Topical Workshop Oral Session 15A

HEART FAILURE WITH PRESERVED EJECTION GLOBAL BURDEN OF HYPERTENSION
FRACTION (HFPEF) AND HYPERTENSIVE HEART Chairpersons: A. Schutte (Sydney, AUSTRALIA),
DISEASE - TWINS OR JUST DISTANT RELATIVES? K. Tsioufis (Athens, GREECE)
Chairpersons: T. Kahan (Stockholm, SWEDEN),
M.L. Muiesan (Brescia, ITALY)
13.00 LECTURE
MENDELIAN RANDOMIZATION IN HYPERTENSION RESEARCH:
13.00-13.15 Epidemiology WHAT CAN IT ADD?
T. Weber (Wels, AUSTRIA) G. Davey Smith (Bristol, UNITED KINGDOM)
13.15-13.30 Physiology - ventricular - vascular interaction 13.15 NATIONWIDE SPATIOTEMPORAL TRENDS IN BLOOD
E. Agabiti Rosei (Brescia, ITALY) PRESSURE AND THE ATTRIBUTABLE CARDIOVASCULAR BURDEN
FROM 2005 TO 2018: A POOLED ANALYSIS OF 13.1 MILLION
13.30-13.45 Treatment PARTICIPANTS IN CHINA
B. Williams (London, UNITED KINGDOM) Y. Kang, X. Wang, P. Yin, Z. Chen, L. Jiang, W. Dong, L. Zhang, C. Zheng,
M. Zhou, Z. Wang, R. Gao
13.45-14.00 Discussion Beijing, CHINA
13.22 CLINICAL CHARACTERISTICS AND BLOOD PRESSURE

TIME-COURSE IN THE YOUNG ACCORDING TO HYPERTENSION
SUBTYPE
F. Saladini 1, L. Mos 2, O. Vriz 2, A. Mazzer 3, C. Fania 1, M. Rattazzi 3,
P. Palatini 1
1
Padua, 2 Udine, 3 Treviso, ITALY
13.29 EPIDEMIOLOGICAL PREVALENCE ESTIMATES OF

HYPERTENSION OF 856,878 ADULTS IN GLASGOW
S. Lip 1, L. McCallum 1, K. Strachan 2, B. McKinstry 2, D. Webb 2,
S. Padmanabhan 1
1
Glasgow, 2 Edinburgh, UNITED KINGDOM
85
13.00-14.00 - ROOM 2
13.36 HOW MANY ADDITIONAL PHYSICIANS ARE NEEDED FOR
HYPERTENSION TREATMENT IN INDIA? Oral Session 15B
M. Marklund 1, M. Marklund 1,2, D. Neupane 3, J.H.Y. Wu 1, B. Neal 1,4,
K. Matsushita 3, L.J. Appel 3
BLOOD PRESSURE MEASUREMENT
1
Sydney, AUSTRALIA, 2 Boston, MA, 3 Baltimore, MD, USA,
4
London, UNITED KINGDOM Chairpersons: A. Mihailidou (Kensington, AUSTRALIA),
13.43 BLOOD PRESSURE TRAJECTORIES FROM CHILDHOOD
TO YOUTH AND ARTERIAL STIFFNESS IN ADULTHOOD: A 30-YEAR
LONGITUDINAL FOLLOW-UP STUDY 13.00 STRIDE BP REVIEW OF PUBLISHED EVIDENCE ON
C. Chu, Y. Wang, J. Mu ACCURATE BLOOD PRESSURE MEASURING DEVICES
Xi’an, CHINA G.S. Stergiou 1, E. O’Brien 2, M. Myers 3, P. Palatini 4, A. Menti 1, A. Kollias
1
, G. Parati 5
13.50 24-H-AMBULATORY BLOOD PRESSURE IN SUB- 1
Athens, GREECE, 2 Dublin, IRELAND, 3 Toronto, CANADA, 4 Padua,
SAHARAN AFRICA: PREVALENCE OF WHITE COAT OR MASKED 5
Milan, ITALY
HYPERTENSION AND DISRUPTED DIPPING PATTERNS IN HIV+
PATIENTS ON ANTIRETROVIRAL THERAPY 13.07 ARTERIAL HYPERTENSION RISK PREDICTION IN
P. Kasper 1, S. Phiri 2, T. Chaweza 2, H. Tweya 2, B. Mwagomba 2, CONDITIONS OF ROTATIONAL SHIFTWORK IN THE ARCTIC
A. Muula 2, A. Nhlema 2, J. Chiwoko 2, F. Neuhann 7, H.-M. Steffen 1,8 N. Shurkevich 1, A. Vetoshkin 2, L. Gapon 1, A. Simonyan 1
1
Cologne, GERMANY, 2 Lilongwe, MALAWI, 3 Lilongwe, MALAWI, 1
Tyumen, 2 Yamburg, RUSSIA
4
Seattle, WA, 5 Chapel Hill, NC, USA, 6 Lilongwe, MALAWI,
7
Heidelberg, GERMANY, 8 Cologne, GERMANY 13.14 CLINICAL CHARACTERISTICS IN THE PATIENTS WITH
MASKED UNCONTROLLED NOCTURNAL HYPERTENSION
MEASURED BY NIGHTIME HOME BLOOD PRESSURE
MONITORING: THE J-HOP NOCTURNAL BP STUDY
K. Narita, S. Hoshide, K. Kario
1
13.21 DIRECT COMPARISON OF HOME VERSUS AMBULATORY

DEFINED NOCTURNAL HYPERTENSION FOR PREDICTING
CARDIOVASCULAR EVENTS: THE J-HOP STUDY
G. Mokwatsi 1, S. Hoshide 2, T. Fujiwara 2, K. Negishi 2, A.E. Schutte 1,
K. Kario 2
1
Potchefstroom, SOUTH AFRICA, 2 Shimotsuke, JAPAN
86
13.00-14.00 - ROOM 3
13.28 ASSOCIATION OF FATAL AND NONFATAL
CARDIOVASCULAR OUTCOMES WITH 24 HOUR MEAN ARTERIAL Oral Session 15C
PRESSURE
J. Melgarejo 1, W.-Y. Yang 1, L. Thijs 1, Y. Li 2, K. Asayama 3, T. Hansen 4,
PRIMARY ALDOSTERONISM
M. Kikuya 3, T. Ohkubo 3, E. Dolan 5, K. Stolarz-Skrzypek 6, Q.-F. Huang 2,
V. Tikhonoff 7, S. Malyutina 8, E. Casiglia 7, L. Lind 8, E. Sandoya 9, Chairpersons: A. Januszewicz (Warsaw, POLAND),
J. Filipovský 10, N. Gilis-Malinowska 6, K. Narkiewicz 6, K. Kawecka-Jaszcz 6, F.H. Shmouni (Bethesda, MD, USA)
J. Boggia 9, J.-G. Wang 2, Y. Imai 3, T. Vanassche 1, P. Verhamme 1,
S. Janssens 1, E.O. Brien 5, G.E. Maestre 10, J. A. Staessen 1, Z.-Y. Zhang 1
1
Leuven, BELGIUM, 2 Shanghai, CHINA, 3 Tokyo, JAPAN, 13.00 RELATIONSHIP BETWEEN THE HYPOTHALMIC-PITUITARY-
4
Tokyo, DENMARK, 5 Capital region of Denmark, IRELAND, ADRENOCORTICAL AXIS ACTIVITY AND THE CHARACTERISTICS
6
Krakow and Gdansk, POLAND, 7 Padova, ITALY, 8 Russia and Sweden, OF ALDOSTERONE-PRODUCING ADENOMAS
ITALY, 9 Montevideo, URUGUAY, 10 Texas, TX, USA M. Thuzar, Y.-C. Lo, Z. Guo, W. Inder, M. Stowasser
Brisbane, AUSTRALIA
13.35 THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHM OF
BLOOD PRESSURE AND LEFT ATRIAL PHASIC FUNCTION IN 13.07 IS POSTOPERATIVE SUBSTITUTION WITH
HYPERTENSION HYDROCORTISONE NECESSARY AFTER ADRENALECTOMY FOR
Y. Liu, Y. Zhao, Q. Sun, Y. Lu, Y. Zhang, W. Song, Y. Cheng, T. Cong, PRIMARY ALDOSTERONISM?
Y. Jiang T. Zelinka, O. Petrak, D. Michalsky, K. Novak, J. Widimsky Jr.
Dalian, CHINA Praha, CZECH REPUBLIC
13.42 MORNING BLOOD PRESSURE SURGE POWER IS A BETTER 13.14 ABDOMINAL AORTIC CALCIFICATION IN ALDOSTERONE
PREDICTOR OF CARDIOVASCULAR DEATH OR EVENTS IN THE PRODUCING ADENOMA AND IDIOPATHIC HYPERALDOSTERONISM
OHASAMA POPULATION THAN PRE-AWAKE VERSUS POST-AWAKE Y. Shibayama, N. Wada, S. Baba, S. Obara, H. Sakai, H. Usubuchi,
MEASURES S. Terae, H. Kameda, A. Nakamura, T. Atsumi
G. Head 1, Y. Sata 1, T. Ohkubo 2,3, M. Kikuya 2, Y. Imai 3, E. Lukoshkova 4 Sapporo, JAPAN
1
Melbourne, AUSTRALIA, 2 Tokyo, 3 Sendai, JAPAN, 4 Moscow, RUSSIA
13.21 BIOCHEMICAL, HISTOPATHOLOGICAL, AND GENETIC
13.49 INVESTIGATING THE ADHERENCE TO THE 5-MINUTE CHARACTERIZATION OF POSTURE RESPONSIVE AND
RESTING INSTRUCTION BEFORE SELF-MEASURING HOME BLOOD UNRESPONSIVE ALDOSTERONE-PRODUCING ADENOMAS
PRESSURE USING ACCELEROMETER-BASED PHYSICAL ACTIVITY Z. Guo 1, K. Nanba 2,3, B.C. McWhinney 1, J.P. Ungerer 1, M. Wolley 1,
DATA R.D. Gordon 1, W.E. Rainey 2, M. Stowasser 1
R. de Heus, C. Maasakkers, J. Claassen 1
Brisbane, AUSTRALIA, 2 Ann Arbor, ML, USA, 3 Kyoto, JAPAN
Nijmegen, THE NETHERLANDS
87
13.00-14.00 - ROOM 4
13.28 BOTH MEDICAL AND SURGICAL TREATMENT FOR
UNILATERAL PRIMARY ALDOSTERONISM LEAD TO BLOOD Workshop
PRESSURE IMPROVEMENTS
T. Puar, P. Kek, L. Ming, W. Loh, D. Lim, P. Tin, M. Zhang, L. Lee,
TREATING HYPERTENSIVE PATIENTS WITH
D. Swee, D. Tay, S. Tan, J. Khoo, R. Foo
Singapore, SINGAPORE DIFFERENT NEUROLOGIC CONDITIONS AND AGE
GROUPS: TARGETS
13.35 HIGH LEVEL OF PLASMA ALDOSTERONE AFTER SALINE Chairpersons: P. Cunha (Guimarães, PORTUGAL),
INFUSION TEST IN COMBINATION WITH FINDING OF ADRENAL D. Hering (Gdansk, AUSTRALIA)
NODE ON CT SCAN CAN PREDICT ALDOSTERONE-PRODUCING
ADENOMA MORE PRECISE THAN FINDING OF NODE ALONE
R. Holaj, J. Kvasnicka, J. Rosa, T. Zelinka, O. Petrak, B. Strauch, 13.00-13.20 The neurovascular and neurodegenerative conditions
Z. Kratka, T. Indra, L. Forejtova, J. Kavan, P. Waldauf, J. Widimsky D. Gasecki (Gdansk, POLAND)
Prague, CZECH REPUBLIC
13.20-13.40 Treatment strategies and BP targets to prevent
13.42 IIMAGING OF PRIMARY ALDOSTERONISM IN YOUNG cognitive decline in hypertension
PATIENTS FROM A LARGE INTERNATIONAL STUDY (AVIS-2- A. Coca (Barcelona, SPAIN)
YOUNG)
G.P. Rossi, F. Crimì 13.40-14.00 Discussion
Padua, ITALY
13.49 THE EFFECT OF RAMIPRIL ON THE ALDOSTERONE/

RENIN RATIO AND THE ALDOSTERONE/ANGIOTENSIN II RATIO IN
PATIENTS WITH PRIMARY ALDOSTERONISM
Z. Guo 1, M. Poglitsch 2, D. Cowley 1, B. McWhinney 1, J. Ungerer 1,
M. Wolley 1, M. Stowasser 1
1
Brisbane, AUSTRALIA, 2 Wien, AUSTRIA
88
CLOSING PLENARY SESSION

Chairpersons: H. Itoh (Tokyo, JAPAN),

DEBATE
HYPERTENSION: IS IT ALL ABOUT ALDOSTERONE?
Chairperson: P. Mulatero (Turin, ITALY)
14.00-14.15 Pro
M. Stowasser (Brisbane-QLD, AUSTRALIA)
14.15-14.30 Against
M. Brown (Cambridge, UNITED KINGDOM)
Athens 2022 Launch

Kyoto 2022 Launch

H. Itoh (Tokyo, JAPAN)
Closing farewell speech from the President

A.F. Dominiczak (Glasgow, UNITED KINGDOM)
89
ORGANISING AND SCIENTIFIC SECRETARIAT
AIM Group International - Rome Office

Via Flaminia 1068 - 00189 Rome ITALY - Ph +39.06.33053.1
Fax +39.06.2332.5630 - hypertension2021@aimgroup.eu - www.hypertension2021.org

ESH-OnAir Programma Web96media

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ESH-OnAir Programma Web96media

Uploaded by

Copyright:

Available Formats

ON-A I R

April 11-14, 2021

11.00-12.00 - AUDITORIUM 12.00-12.45 - AUDITORIUM

OPENING OF THE CONGRESS Minisymposium

ADVANCES IN TECHNOLOGY, PIONEERING NEW

12.15-12.25 Patient populations at risk for cardiac events related to

12.25-12.35 Casuistry: consequences of nocturnal hypertension in

12.00-13.00 - ROOM 1 12.00-12.45 - ROOM 2

Joint Session ESH-ISH-POA Minisymposium

12.35-12.45 General Discussion

*Single Pill Combinations

12.45-12.55 Metabolic syndrome in spontaneously hypertensive rats

12.00-12.05 Opening Remarks and Welcome Speech

12.05-12.15 Integrative genomic analysis of blood pressure in rats

12.15-12.25 What genetics of blood pressure teaches us about

12.25-12.30 Brain perivascular macrophages contribute to the

12.30-12.35 Effects of blood pressure and salt on arterial lipid

12.45-13.00 Panel discussion and Q&A

12.00-13.00 - ROOM 5 12.30-13.30 - ROOM 6

ESH Working Group on Hypertension and ESH Working Group on Interventional

12.48-13.00 Recommendations of the WG on Hypertension and the

13.00-14.00 - AUDITORIUM 13.00-14.00 - ROOM 1

Satellite Symposium ESH Working Group on Vascular Structure

13.00-13.05 Introduction 13.00-13.05 Introduction

13.00-14.00 - ROOM 2 13.00-14.00 - ROOM 3

ESH Working Group on Obesity, Diabetes ESH Working Group on Hypertension

13.00-13.10 Early life programming of CVD

13.50-14.00 Discussion 13.40-13.50 The need for a global call to action

13.00-14.00 - ROOM 5 13.30-14.30 - ROOM 6

ESH Working Group on Cardiovascular ESH Working Group on Hypertension and

13.54-14.06 The management of hypertensive patients with HFpEF.

14.06-14.30 Organization and future projects of the WG

14.00-15.00 - AUDITORIUM 14.00-15.00 - ROOM 1

Satellite Symposium ESH Working Group on Hypertension in

14.15-14.25 Emerging consensus for renal denervation: regional 14.50-15.00 Discussion

14.25-14.50 Renal denervation in the real-world: performance in

14.50-15.00 Live Q&A

14.00-15.00 - ROOM 2 14.00-15.00 - ROOM 3

M. Barton (Zurich, SWITZERLAND)

14.10-14.20 The effects of sleep quality on overall BP control in

14.20-14.30 Mineralo corticoid receptor antagonists for

14.30-14.40 SGLT-2 inhibitors for nephroprotection in non-diabetic

14.40-14.50 Hypertension in patients with renal transplantation:

ESH Working Group on Hypertension and CASE 3

SEXUAL DYSFUNCTION AND ANTIHYPERTENSIVE 14.46-14.48 Discussion

Chairpersons: D. Lovic (Niš, SERBIA), CASE 4

14.00-14.12 Current clinical practice and future directions 14.58-15.00 Discussion

14.00-15.00 - ROOM 5 15.00-15.45 - AUDITORIUM

ISH Regional Advisory Group - Africa Minisymposium

15.00-15.45 - ROOM 1 15.00-15.45 - ROOM 2

15.00-15.03 Welcome and introduction

15.00-16.00 - ROOM 3 15.00-16.00 - ROOM 4

The Balkan Symposium Oral Session 1A

15.00-15.10 BP CON ESH-report on first 3000 subjects

15.35 SODIUM ACETATE ATTENUATES MYOCARDIAL

15.14 PROTEOMIC ASSESSMENT OF CIRCULATING

15.21 A NEW GENETIC RISK SCORE FOR BLOOD PRESSURE

16.00-16.45 - AUDITORIUM 16.00-16.45 - ROOM 1

HITTING THE BULL’S-EYE IN HYPERTENSION IMPROVING CARDIORENAL OUTCOMES IN

16.00-16.10 CVD and CKD in diabetes and hypertension

16.00-16.45 - ROOM 2 16.00-17.00 - ROOM4

Minisymposium Late-Breakers Oral Session

16.35 BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE